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My thesis focuses on understanding the functional role of SRSF1, a prototypical 
splicing factor, in the context of liver physiology. I began by generating and characterizing 
hepatocyte-specific SRSF1 knock-out mice models. These mice developed severe liver 
damage and exhibited pathology like the human disease Non-alcoholic steatohepatitis. 
Specifically, loss of SRSF1 results in immediate cell death and triggers a regenerative 
response in the liver. While SRSF1 was initially discovered as a splicing factor, studies 
since its discovery have revealed it plays multiple roles in RNA biology. This ranges from 
mRNA transport, translation regulation, non-sense mediated decay, and even processing 
of miRNA. Therefore, it is not surprising that SRSF1 is vital for the survival of the cell. 
While a deficiency in most tissues results in organ failure, the liver has the remarkable 
capability to circumvent the Cre-lox based knock-out of SRSF1. However, the chronic 
cycle of death and regeneration leads to the development of NASH-like pathology. 
To understand primary changes occurring in the model, an acute SRSF1 knock-
out model was developed. Insight into the molecular basis of the pathology was gained 
using transcriptome- and proteome-wide approaches such as RNA-Seq, eCLIP-Seq, and 
mass spectrometry. Extensive investigation of the molecular mechanism underlying the 
pathology revealed loss of SRSF1 activity leads to widespread DNA damage and defects 
in global translation. With the widespread damage, SRSF1 deficient hepatocytes 
eventually undergo necroptosis leading to failure of the liver. Moreover, these defects 
were also observed in siRNA mediated knockdown of SRSF1 in HepG2 cells, a human 
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The global burden of liver-related diseases is large and steadily increasing. With 
the growing world-wide epidemic of metabolic syndrome, the prevalence of nonalcoholic 
fatty liver disease (NAFLD) is also rising (Asrih and Jornayvaz 2015). Recent reports 
estimate that about one-third of the United States population is affected with this disease. 
NAFLD is a metabolic disorder in which fat accumulates within the liver (steatosis) and 
can result in inflammation, hepatic injury, and cirrhosis without significant consumption of 
alcohol (Vernon, Baranova, and Younossi 2011). There have been significant efforts 
made to understand the genetic aspects that may predispose an individual to this disease. 
A recent study examining SNPs in patients with NAFLD revealed a significant association 
for pathways involved in mRNA splicing, an essential post-transcriptional processing step 
(Chen et al. 2013). Indeed, there are now numerous studies showing the importance of 
post-transcriptional gene regulatory mechanisms (PTGRM) in maintaining proper liver 
physiology and metabolic output. Understanding how these regulatory networks are 
coordinated with hepatic functions will provide valuable insight for the discovery and 
development of novel therapeutic targets and approaches. 
RNA-binding proteins (RBP) is the broad class of proteins which act on mRNA and 
mediate post-transcriptional regulation. This study investigates a well characterized RBP, 
SRSF1, and its role in maintaining liver function and homeostasis. To study the function 
of this protein in-vivo, I generated and extensively characterized two variants of 
hepatocyte-specific knockout mice models: a transgenic model and a viral mediated 
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model. These mice models revealed that loss of SRSF1 in hepatocytes results in 
spontaneous accumulation of lipids within the cells and subsequent death.  
To gain molecular insight into the mechanism of the pathogenesis, both RNA-Seq 
and mass spectrometry techniques were utilized to capture transcriptome and proteome 
changes occurring in these models. The results from this study show that SRSF1 is crucial 
for the stability of the genome with loss of its activity causing widespread DNA damage. 
Specifically, deficiency of SRSF1 results in extensive formation of R-loops which are 
three-stranded structures composed of a DNA-RNA hybrid and the associated non-
template single-stranded DNA. Accumulation of R-loops leads to DNA double strand 
breaks as the cell fails to resolve these structures. Furthermore, this leads to subsequent 
impairment of global translation and eventual cell death by necroptosis. Reduction in 
global translation limits the metabolic functionality of the liver resulting in subsequent 
failure of the tissue. Furthermore, analysis of RNA-Seq data of SRSF1 knockdown in 
HepG2, a human hepatocellular carcinoma cell line, corroborates the phenotypes 
observed in the mice model. In brief, this study shows that the activity of SRSF1 is 
required for the proper functioning of hepatocytes and is vital for cellular physiology in 
general. 
1.2 Liver Anatomy and Function  
It is estimated that the liver performs nearly 500 different functions in the body, 
thus exemplifying its importance. It is primarily a metabolic organ, with functions ranging 
from but not limited to detoxification, digestion, and processing nutrients. The liver can 
simply be viewed as a blood filtration system both functionally and structurally. 
Substances and nutrients absorbed by the gastrointestinal (GI) tract are first directed to 
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the liver via a special venous system, known as the hepatic portal system (Gebhardt 
1992). Within this first pass, nutrients present in the blood are taken up and processed to 
allow for systemic delivery. Furthermore, it allows the blood to be detoxified of xenobiotics 
and excreted before it can cause harm to the body (Sanchez and Kauffman 2010). 
Viewing the liver at the histological scale, its organization bears resemblance to a simple 
filtration system. The hepatic lobule is defined as the smallest functional unit of the liver 
which is comprised of the portal triad, central vein and sinusoids lined with hepatocytes 
bridging the two vasculatures (Figure 1.1) (Ben-Moshe and Itzkovitz 2019).  Partially 
deoxygenated but nutrient rich blood from the GI enters the liver through the portal vein 
and is conducted into the sinusoidal capillary beds that perfuse through the liver. The 
sinusoid is lined with hepatocytes and a fenestrated endothelium allowing contents of the 
blood to exchange with the hepatocytes and vice versa. The blood then leaves the tissue 
through the central vein which eventually leads into the inferior vena cava. 
 
 




The cell types of the liver can be classified into two broad types: parenchymal cells 
or hepatocytes and non-parenchymal cells. Hepatocytes constitute about 70% of the liver 
mass and perform the major functions of the liver such as metabolizing nutrients and 
drugs or secreting factors into the blood like albumin and clotting factors to name a few. 
Hepatocytes also produce bile which is eventually secreted into the small intestine for the 
digestion and absorption of lipids. While blood within the tissue flows from the portal triad 
to the central vein, bile flows within the bile canaliculi in the opposite direction towards the 
bile duct which is part of the portal triad. The non-parenchymal cells (NPC) which make 
up the remainder of the liver consist of cholangiocytes, sinusoidal cells, stellate cells and 
Kupffer cells (Si-Tayeb, Lemaigre, and Duncan 2010). Although they represent a smaller 
fraction, these cells are crucial for the proper development and functioning of the liver. 
Moreover, NPCs, such as Kupffer and stellate cells, play an important role in mounting 
defense response to mitigate damage from hepatotoxic stresses. Kupffer cells are the 
resident macrophages involved in the innate immune response and clearing away any 
pathogens (Liu et al. 2010). Stellate cells are normally quiescent, however, upon liver 
injury they become activated and release collagen to repair tissue damage (Poisson et 
al. 2017; U. E. Lee and Friedman 2011).  
The liver plays an essential role in processing and systemic delivery of 
macronutrients obtained through our diet. There are two main metabolic states that a 
body experiences; fed (absorptive) or fasted (post-absorptive). Depending on the 
metabolic state, the liver behaves differently in response to an intricate feedback system 
involving hormones. Under fasting conditions, when blood glucose levels are low and 
glucagon levels are high, the liver breaks down glycogen stores into glucose and releases 
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it into the bloodstream. On the contrary, when glucose and insulin levels are elevated 
following a meal, gluconeogenesis is inhibited, and synthesis of fat, protein and glycogen 
are promoted in the liver (Galgani and Ravussin 2008; Patterson and Sears 2017). 
Metabolism in the liver is a vast and complex topic, however, for this current work, a brief 
overview of lipid processing and delivery is provided. 
1.2.1 Packaging of Dietary Lipids and Export in the Liver 
The liver plays a central role in metabolizing of lipids and exporting it throughout 
the body. There are three primary sources by which hepatocytes obtain triglycerides (TG): 
(1) de novo lipogenesis, (2) dietary TG entering as particles known as chylomicron 
remnants after feeding or (3) free fatty acids released from adipose tissue stores under 
fasting conditions (Figure 1.2). With increased mobilization of TG into the liver, there is a 
simultaneous increase in its packaging and efflux into circulation. Before TG can be 
exported into circulation, they are first packaged into structures known as lipoprotein 
particles within the hepatocytes. These particles are composed of a hydrophobic core 
containing TG and cholesterol esters (CE) surrounded by a hydrophilic surface consisting 
of phospholipids (PL), free cholesterol and apolipoproteins (Zhou et al. 2015). Formation 
of these particles begin within the lumen of the endoplasmic reticulum (ER). The first step 
in the process is the translation of apoB transcript at the rough ER and its translocation 
into the lumen (Davidson and Shelness 2000). Proper folding and lipidation of this large 
protein into a primordial particle are facilitated by an essential factor called microsomal 
triglyceride transfer protein, MTTP. This factor is also responsible for forming lipid droplets 
within the lumen using TG present within the lumen and smooth ER. Finally, facilitated by 
MTTP, the lipid droplet is assembled with the primordial apoB particle resulting in a very-
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low-density lipoprotein (VLDL) particle which is secreted into circulation through the Golgi 
(Figure 1.2). Proper folding and lipid loading are necessary for the stability of apoB, 
otherwise the molecule becomes rapidly ubiquitinated and degraded. This can occur 
during conditions where lipid or MTTP levels are low (Hussain et al. 2012; Raabe et al. 
1998). Although this may seem like an inefficient mechanism to regulate VLDL formation, 
it provides the hepatocyte the ability to rapidly adapt to changing environments. In 
conclusion, each step of the lipid packaging process is vital to maintaining proper 
functioning of the tissue and impairment at any step can result in the build of TG within 
the hepatocyte and development of steatosis. 
 
 
 Assembly of Lipoprotein Particles in Hepatocytes  
Schematic providing a simplified representation of Lipoprotein particle formation within 
hepatocytes. Lipoprotein particles are formed within the ER lumen through the assembly 
of lipid droplets with newly synthesized lipoproteins. Formation of the particles is 
facilitated by MTTP. DNL, De novo lipogenesis; MTTP, microsomal triglyceride transfer 




1.3 Post-Transcriptional Gene Regulation1 
1.3.1 Introduction 
Unlike prokaryotes, eukaryotic transcription and translation take place in separate 
cellular compartments, the nucleus, and cytoplasm, respectively. This physical 
uncoupling forces newly transcribed mRNA to journey into the cytoplasm before being 
translated into protein. It is now known that along this journey, an mRNA transcript 
experiences numerous interactions with various factors and undergoes extensive 
remodeling (Hocine, Singer, and Grünwald 2010). This diverse set of processing events 
includes capping, splicing, and polyadenylation and as with most biological processes, 
they are highly regulated, dynamic, and dependent upon the state and type of the cell. In 
general, these mechanisms regulate gene expression by altering the following properties 
of RNA: its stability, localization, translation efficiency, and nucleotide sequence. 
Collectively, these are referred to as post-transcriptional gene regulatory mechanisms. 
1.3.2 Mechanisms of Regulation in Metabolism 
Although metabolic activity is largely dictated by transcription factors and the 
synthesis of new mRNAs, the production of new transcripts alone does not result in 
greater protein expression.  Each nascent transcript must first undergo a series of 
processing steps including splicing, chemical base modifications, and 3’ end formation to 
be successfully translated within the cytoplasm. Thus, the process of new transcription 
 
1 Reproduced in part with permission from 
  
Arif, W., Datar, G., and Kalsotra, A. Intersections of post-transcriptional gene regulatory 
mechanisms with intermediary metabolism. Biochim. Biophys. Acta. (2017) 1860(3), 349-362. 




and protein synthesis may require hours to days to exert cellular effects. Given the delay 
between transcriptional activation and response, a cell can adapt to rapidly shifting 
metabolic conditions by mediating changes to the existing mRNA pool at the level of 
mRNA sequence, stability, and translation efficiency. To that end, numerous post-
transcriptional regulatory mechanisms have evolved to regulate RNA processing and 
control gene expression. While various mechanisms of PTGRM exist, for this work only 
alternative splicing and translation regulation will be reviewed. 
Alternative Splicing 
The sequence of each mRNA largely defines its function, stability, and translation 
efficiency. During mRNA maturation, this sequence may be modified from the original 
coding gene by RNA splicing, a process by which non-coding introns are removed, and 
coding exons are ligated together. Importantly, the pattern in which introns and exons are 
spliced can vary within the same transcript in a process known as alternative splicing 
(AS). AS is perhaps the most well-understood regulatory step within RNA processing, and 
plays an important role in the expanding diversity of the eukaryotic proteome; 95% of 
human multi-exon genes experience a form of AS that can lead to exon skipping, 
alternative 3’ and 5’ splice sites, intron retention, and mutually exclusive exon inclusion 
(Pan et al. 2008; Y. Lee and Rio 2015). In this way, a single gene may produce multiple 
transcripts and proteins with varying function, stability, and localization. A specialized 
class of RNA binding proteins (RBP) known as splicing factors mediates the splicing of 
alternative exons by binding to RNA elements known as exonic splicing enhancers (ESE) 
and suppressors (ESS). AS is central to normal physiological function, and aberrant 
splicing has been implicated in several disease pathologies.  
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Likewise, several studies have shown that AS is integral to maintaining metabolic 
state and responding to physiological changes. Specifically, changes in metabolic state 
may alter the splicing pattern or efficiency of important metabolic regulators. Peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a major 
transcriptional activator that has been shown to be extremely important for skeletal 
muscle remodeling, mitochondrial biogenesis, and angiogenesis. Variations in skeletal 
muscle training were found to induce a splicing switch in PGC-1α mRNA, producing the 
α1 and α4 isoforms. Endurance training generates the α1 isoform and leads to increases 
in oxidative phosphorylation genes and myosin switching. Unlike the α1 isoform, the α4 
isoform of PGC-1α interacts with separate targets like Insulin-like growth factor 1 (IGF-1) 
and genes in the myostatin pathways to induce skeletal muscle hypertrophy in response 
to resistance training (Ruas et al. 2012). Furthermore, studies have outlined the role of 
alternative splicing regulation in cholesterol metabolism. 3-Hydroxy-3-Methylglutaryl-CoA 
Reductase (HMGCR), the rate-limiting enzyme in the cholesterol biosynthetic pathway, is 
a target of heterogeneous nuclear ribonucleoproteins A1 (hnRNP A1), a prominent 
regulatory protein and splicing factor.  An HMGCR SNP in the binding area of hnRNP A1 
was shown to promote skipping of exon 13, leading to inactivation of HMGCR activity and 
increased LDL-C uptake (Yu et al. 2014). Additionally, sterol loading has been 
demonstrated to induce the splicing and inactivation of HMGCR and LDLR by another 
prominent splicing factor known as Polypyrimidine Tract Binding Protein 1 (PTBP1) 




1.4 The SR Protein Family 
The SR proteins are a family of phylogenetically conserved and structurally related 
RNA binding proteins which have essential roles in constitutive and alternative splicing of 
pre-mRNA. This family consists of 12 canonical members, all of which have a modular 
structure consisting of up to two N-terminal RNA-recognition motif (RRM) followed by a 
C-terminal RS domain which is rich in alternating serine and arginine residues (Howard 
and Sanford 2015; Zahler et al. 1992). These domains are functionally independent in 
splicing. In general, the RRM domains determine the RNA-binding properties while the 
RS domain mediates protein-protein interactions and is involved in orchestrating 
components of the spliceosome machinery. RS domains also provide nuclear localization 
signals for the SR protein. Depending on the strength of the localization signal of a given 
RS domain determines the nucleocytoplasmic shuttling activity of the associated SR 
protein. For instance, SRSF1 shuttles readily between the nucleus and cytoplasm while 
SRSF2 strictly resides within the nucleus.  
Overall, SR proteins are considered to play roles in both constitutive and 
alternative splicing of pre-mRNA. While this statement seems counter intuitive, it can be 
rationalized by the modular aspect of SR protein. There is strong evidence which show 
that SR proteins are essential at multiple steps of spliceosome assembly (Long and 
Caceres 2009). However, selection of cis-acting elements by RRM domains give SR 
proteins to behave as alternative splicing factors. Although SR proteins play roles in 
housekeeping functions of the cell, an increasing number of studies are showing that 




1.4.1 The Role of SR Proteins in Metabolism 
Recent studies are now providing evidence of SR proteins playing roles in 
metabolic regulation in tissue. For example, splicing factor arginine/serine-rich 10 
(SFRS10) was shown to be downregulated in the liver and skeletal muscle tissues from 
obese patients. Lipin-1 (LPIN1), a key regulator of lipid metabolism, is a putative target of 
SFRS10 and exists in two major splice isoforms. Co-transfection of SFRS10 and a 
minigene construct containing alternative exon 6 of LPIN1 induced exon 6 skipping while 
SFRS10 siRNA led to an increase in exon 6 inclusion.  Interestingly, the SFRS10 binding 
site overlaps with U1 snRNA binding sites at the 5’ splice site, suggesting that binding of 
SFRS10 disrupts snRNA activity. Downregulation of SFRS10 favors the LPIN1B isoform, 
leading to an increase in lipogenesis mediated by upregulation of Srebp1c and Fatty acid 
synthase (FASN). Moreover, SFRS10 heterozygosity results in increased VLDL secretion 
and hypertriglyceridemia in mice (Dong et al. 2016). 
Regulating G6PD splicing is central to the cell’s ability to respond to changing 
metabolic states. Exon 12 of G6PD pre-mRNA contains a regulatory element that controls 
splicing efficiency. Under fasting conditions, upregulation of the splicing factor hnRNP K 
led to decreased splicing and expression of G6PD mRNA. Two C-rich motifs within exon 
12 of G6PD form an ESS site leading to exon skipping and diminished splicing upon 
hnRNP K binding. Remarkably, these motifs also function as an ESE site for 
Serine/Arginine-Rich Splicing Factor 3 (SRSF3). Under nutrient-rich conditions, insulin 
induces SRSF3 activity through the phosphorylation of SR proteins. SRSF3 can then bind 
G6PD pre-mRNA and promote exon inclusion to increase G6PD expression (Walsh et al. 
2013; Cyphert et al. 2013). Furthermore, it has recently been shown that SRSF3 is crucial 
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for hepatocyte differentiation. Deletion of SRSF3 in hepatocytes resulted in aberrant 
splicing of key metabolic genes necessary for glucose and lipid metabolism (Sen, Jumaa, 
and Webster 2013). In conclusion, there is an emerging notion that SR proteins can play 
roles in regulating key metabolic functions of a cell 
1.5 Overview of SRSF1 
SRSF1 is considered the prototypical SR protein as it was one of the first SR 
proteins to be identified and has been the most studied SR protein. Since its initial 
discovery as a factor required to complement splicing activity in S100 Hela cell extract, 
SRSF1 has been found to function in numerous processes within a cell (Krainer, Conway, 
and Kozak 1990).  
1.5.1 Structure and Function of SRSF1 
As mentioned previously, SR proteins contain modular domains which are linked 
together by flexible hinge regions. In the case of SRSF1, it contains two N-terminal RRM 
domains and a C-terminal RS domain (Figure 1.3). As the name implies, RRM domains 
in SRSF1 provide it the capacity to bind RNA in a sequence specific manner. SRSF1 is 
involved in selection of splice sites by binding to cis-acting elements on pre-mRNA. 
Moreover, studies have found there to be positional dependence on SRSF1’s effect on 
splice site selection as well.  
 




In general, binding of SRSF1 within exonic regions tend to enhance splice site 
selection and are therefore known as exonic splicing enhancer regions or ESE’s while 
intronic binding sites tend to repress selection (Figure 1.3). It is suggested that SRSF1 
binding to exons allows it to recruit and stabilize interactions of the U1 snRNP on the 5’-
splice site with U2AF on the 3’-splice site. This bridging of spliceosome factors across the 
exon is known as exon definition. It is thought the exon definition predominates in 
eukaryotic systems as genes tend to have short exons with long introns. Therefore, 
defining exons within a mRNA sequence is thermodynamically more favorable.  
While RRM domains facilitate RNA interactions, the RS domain is involved in 
mediating protein-protein interactions. This domain is rich in serine and arginine residues 
which bestow interesting properties. The rich serine concentration of the RS domain 
allows for extensive phosphorylation. This modification allows for the domain to go from 
highly positively charged (from the arginine residues) to highly negatively charged. This 
change in electrostatic states allows for dynamic interactions with RNA and other 
proteins. Furthermore, phosphorylation of this domain is highly dynamic with studies 
showing SRSF1 undergoing multiple phosphorylation and dephosphorylation cycles 
during splicing. Interestingly, conditions where SRSF1 is kept either hyper- or 
hypophosphorylated, its splicing activity is inhibited. Phosphorylation also modulates the 
subcellular localization of SRSF1 as phosphorylation of the RS domain allows reentry into 
the nucleus. Taken together, the modular domains of SRFS1 are highly dynamic and 




1.5.2 Additional Activities of SRSF1 in Various Cellular Processes 
In addition to splicing, studies have shown SRSF1 to exhibit activities in essentially 
every aspect of gene expression regulation such as mRNA export, nonsense mediated 
decay, and translation to name a few (Das and Krainer 2014). A few of these activities 
will be discussed briefly. 
Transcription and Genome Stability. There is well-documented evidence that 
splicing of mRNA occurs co-transcriptionally. Therefore, it is not surprising that SRSF1 
has been found to interact with the RNA polymerase II complex. In fact, this interaction 
has been found to increase the efficiency of transcription. It is believed that co-
transcriptional splicing facilitates release of RNA from the template DNA and further 
reduces supercoiling as the DNA can close behind the moving transcription bubble. 
Without co-transcriptional splicing, nascently transcribed RNA have a higher propensity 
to stay associated to the template DNA forming DNA-RNA hybrid structures known as R-
loops (Tous and Aguilera 2007; Belotserkovskii et al. 2017). R-loops are potentially 
problematic as these structures are prone to DNA damage due to the exposed single 
strand DNA. While these structures occur naturally at some low frequency in active cells, 
these are not detrimental as healthy cells possess mechanisms to resolve these 
irregularities (Sollier and Cimprich 2015; Santos-Pereira and Aguilera 2015). However, 
under conditions of increased frequency of R-loop formation, a cell can easily become 
overwhelmed leading to DNA double strand breaks as the cell fails to resolve these 
structures. 
There is now substantial evidence linking splicing activity to genome integrity. In 
fact, SRSF1 has been shown to be vital for maintaining genome stability. A 2005 study 
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by Li and Manley very elegantly showed that inactivation of SRSF1 in DT40 cells, a 
chicken B cell line, led to genomic instability. Specifically, loss of SRSF1 resulted in the 
accumulation of R loops which led to subsequent DNA damage by double strand breaks 
(X. Li and Manley 2005). This finding suggests that SRSF1 confers protection to the 
genome by the deleterious effects of transcription itself. SRSF1 prevents the formation of 
R loop by binding to nascently transcribed mRNA and preventing it from associating to 
template DNA. 
mRNA Export. As mRNAs are co-transcriptionally spliced, a multiprotein complex 
known as the exon junction complex, or EJC, is deposited on the mRNA in a sequence 
independent manner. SRSF1 is one of the proteins that makes up the EJC (Mabin et al. 
2018; Hir, Saulière, and Wang 2016). While this complex serves multiple purposes such 
as compacting the mRNA and providing stability, it also facilitates mRNA export to the 
cytoplasm. SRSF1 is a key player in mediating mRNA export. Specifically, it can act as 
an adaptor protein by binding directly to export factors such as TAP or Nuclear export 
factor 1 (NXF1) which then transports the RNP complex out to the cytoplasm (Müller-
McNicoll et al. 2016; Huang, Yario, and Steitz 2004). 
Translation. Of the SR proteins, SRSF1 is one of the three that displays 
nucleocytoplasmic shuttling activity. It was initially thought that SRSF1 may play a role in 
regulating translation in the cytoplasm. Soon after, a study in Hela cells showed that 
SRSF1 was found associated to polyribosomes in cytoplasmic extracts and that it 
enhanced the translation efficiency of its target (Sanford et al. 2004). Furthermore, it was 
shown that SRSF1 stimulates translation by promoting translation initiation of mRNA 
targets by suppressing 4E-BP activity, a known translation inhibitor, in a mTOR 
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dependent manner (Michlewski, Sanford, and Cáceres 2008). Additionally, it was found 
that splicing targets of SRSF1 had a greater propensity to be exhibit SRSF1 mediated 
translation regulation. This is one of the first examples of a factor with activities involved 
in coupling splicing and translation.  
In conclusion, SRSF1 is a highly versatile factor with activities in numerous aspects 
of gene expression besides co- and post-transcriptional splicing. In addition to the 
functions described here, SRSF1 can regulate microRNA processing, nonsense 
mediated decay and nucleolar stress response. An increasing number of studies have 
focused on the cellular effects of SRSF1 overexpression. In fact, SRSF1 is considered a 
proto-oncogene as it can potentate cancer development. (Anczuków et al. 2012; Das et 
al. 2012). Fewer studies have investigated the effects of SRSF1 depletion. This is not 
surprising as SRSF1 possesses many functions its loss will result in lethality of the cell. 
In this study we decided to explore the effects of SRSF1 knockout in liver. As expected, 
loss of SRSF1 was detrimental to hepatocytes leading to robust cell death.  
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 Phenotypic Characterization of Hepatocyte-
Specific SRSF1 Knock-out Mice Model 
 
2.1 Introduction 
As mentioned in section 1.4, homozygous deletion of the SRSF1 allele results in 
embryonic lethality in all animal models tested thus far. To circumvent this issue and study 
the role of SRSF1 in liver, we generated hepatocyte-specific SRSF1 knock-out mice 
(SRSF1 HKO) by intercrossing SRSF1 floxed mice with Alb-Cre transgenic mice. Since 
there have been no previous study of regarding SRSF1’s role in liver, characterization of 
the phenotype was performed using histological and serum analysis at various time-
points in development. Previous studies using the Albumin-Cre transgenic mice report 
Cre to be homogenously active around embryonic day 18.5. For this reason, tissues were 
harvested at early time points up to 10 days after birth as well as later time points in 
development starting at 5 weeks. Histological analysis provides valuable insights into 
microscopic changes occurring of the tissue anatomy. Various stains have also been 
performed to allow for understanding different aspects of the tissue architecture. Similarly, 
analysis of specific serum parameters can provide useful information regarding the status 




2.2 Material and Methods 
The following sections provides details of the materials and methodology utilized 
for the studies performed in this chapter. For details on additional methodology including 
western blot analysis, histological staining, immunohistochemistry, and 
immunofluorescence staining, refer to Section 9.1: Supplementary Protocols. 
2.2.1 Generating Hepatocyte-specific SRSF1 Knockout Mice Model 
Mice with floxed alleles for SRSF1, developed by Dr. Xiang-Dong Fu and available 
from The Jackson Laboratory, were bred with mice expressing the Cre-recombinase 
driven by the Albumin promoter to obtain hepatocyte-specific SRSF1 knockout (SRSF1 
HKO) mice (Figure 2.1) (X. Xu et al. 2005; Postic et al. 1999). The mice were housed on 
a standard 12-hour-light/dark cycle and fed a normal chow diet (2918 Envigo Teklad). 
The mice were fasted for 9 to 10 hours prior to harvesting tissues for subsequent analysis. 
National Institutes of Health (NIH) guidelines for use and care of laboratory animals was 
followed and all the experiments were approved by the Institutional Animal Care and Use 
Committee at the University of Illinois at Urbana-Champaign.  
2.2.2 Blood Collection and Serum Chemistry Analysis 
Mice were fasted about 10 hours prior to blood collection. Blood was collected from 
mice by bleeding them from the retro-orbital venous sinus using EDTA coated blood 
collecting capillaries. Mice were temporarily anesthetized using isoflurane before 
collecting blood. For non-terminal procedures about 200 µL was collected otherwise 
about 600 µL was collected. Blood from the capillary was transferred into BD microtainer 
tubes and then centrifuged according to manufacture’s protocol to separate the serum. 
Serum was then transferred into 1.5 mL microcentrifuge tubes and snap frozen in liquid 
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nitrogen before storing at -80 °C. Serum cholesterol, triglycerides, ALT and AST activity 
were measured using colorimetric assay kits provided by Infinity (Thermo Scientific). 
Serum bilirubin, both direct and indirect, were measured using the Sigma Bilirubin Assay 
kit (MAK126 Sigma) according to the manufacturer’s protocol. 
2.2.3 Glucose Tolerance Test in Mice 
Mice were fasted overnight and injected with D-glucose at 2g/kg intraperitoneally. 
Blood glucose concentrations were measured at 0, 15, 30, 45, 60 and 120 min after 
glucose injections using the One Touch glucose meter. Blood for measurement was 
obtained from the tip of the tail after clipping. 
2.2.4 Generating Diet Induced Hepatic Steatosis Mice Model 
Starting at 8 weeks of age, C57B/6J mice were fed 60% high fat diet (Envigo 
Teklad) for 8 weeks to mimic obese conditions. Mice were sacrificed at the end of the 
experimental regimen. Liver and white adipose tissues were collected for gene 





 Generating Hepatocyte-Specific SRSF1 KO Mice Model 
The SRSF1 Flox mice have LoxP sites flanking exons 2 through 4 resulting in significant 
removal of the open reading frame. The breeding schema was used to generate SRSF1 




2.3.1 Loss of SRSF1 in Hepatocytes Results in Immediate Development of Steatosis 
SRSF1 HKO mice exhibit immediate and robust development of lipid accumulation 
within the liver tissue. This is apparent from the gross appearance of the liver tissue 10 
days after birth (Figure 2.2 A). Compared to controls, SRSF1 HKO livers at this stage 
are strikingly yellow in color, signifying an accumulation of fat within the tissue. Mice at 
this age also weigh less than littermate control mice (Figure 2.2 B). 
Histological staining was performed on tissue sections at early timepoints in 
development to gain further insight into the pathology (Figure 2.3). Hematoxylin and 
Eosin staining was performed to observe general morphological changes occurring in the 
tissue and Oil Red O staining was performed to qualitatively assess the extent of lipid 
accumulation within the tissue. From the staining it is apparent that starting at 6 days after 
birth, hepatocyte death can be observed in SRSF1 HKO livers. Hepatic cell death is 
observed at later timepoints as well. With regards to hepatic lipid levels, both control and 
SRSF1 HKO show significant accumulation of lipids in the tissue up to 6 days of age. 
However, after 6 days, control livers show severe reduction in lipids within the tissue 
whereas SRSF1 HKO have persistent accumulation (Figure 2.3). 
To assess the knockout efficiency of SRSF1 in this mice model, western blot 
analysis was performed on isolated hepatocytes. Interestingly, we find about a 60% 
reduction in SRSF1 levels in hepatocytes 10 days after birth (Figure 2.2 C). However, 
previous reports have shown that the albCre transgenic driver results in nearly complete 
conversion of hepatocytes by postnatal day 3 using a Cre-dependent fluorescent reporter 
(Postic et al. 1999; Weisend et al. 2009). Reduction of SRSF1 observed in our model can 
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be a rationalized with the following possibilities; (1) there is a 60% reduction in SRSF1 
levels in all hepatocytes or (2) about 60% of hepatocytes are have SRSF1 knocked out 
while the remaining 40% are still expressing SRSF1 at wildtype levels. 
To distinguish between the two possible mechanisms, an immunofluorescent 
staining was performed on tissue sections from control and SRSF1 HKO livers (Figure 
2.4). An advantage of this technique is that it allows for the probing of multiple factors. 
Therefore, in addition to probing for SRSF1, the tissue section is also probed for HNF4A, 
a hepatocyte specific marker. This allows for efficient identification of hepatocytes within 
a field and subsequent quantification of SRSF1 within those cells. Quantification is 
performed using custom ImageJ scripts (Figure 2.5 A). Greatest knockout of SRSF1 
within hepatocytes is observed 6 days after birth. After this point, the liver tissue begins 
to slowly repopulate with SRSF1 expressing hepatocytes. Tissue sections were also 
stained for Ki67, a cell division marker, to allow for comparison of proliferation between 
controls and SRSF1 HKO (Figure 2.4). Quantification of proliferating hepatocytes reveal 
that the fraction of proliferating cells decreases at 6 days in SRSF1 HKO, but then 
increases afterwards (Figure 2.5 B). 
2.3.2 Development of NASH-like Pathology in SRSF1 HKO Mice 
While livers of SRSF1 HKO mice can circumvent knockout of SRSF1 in the liver, 
these mice still develop severe pathology. Gross inspection of liver tissue at the five-week 
and three-month timepoint show steatosis (paler color), however, the severity is far less 
in comparison to ten-day livers. At 5 weeks, western blot analysis shows about 2-fold 
reduction in abundance compared to controls (Figure 2.6 C). Characterization of SRSF1 
HKO shows a growth retardation phenotype with elevated ALT and AST levels starting at 
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five-week timepoint signifying liver damage (Figure 2.6 A-B and 2.8 A). However, by six 
months these mice catch up in growth to controls and exhibit no difference in ALT and 
AST levels. Earlier timepoints also have decreased levels of cholesterol and triglycerides 
at the 5 weeks and 3 months timepoints (Figure 2.8 A). Furthermore, at 8 weeks, glucose 
tolerance testing of control and SRSF1 HKO mice do not show any significant differences 
(Figure 2.8 B) 
This is in agreement with the hypothesis that the hepatocytes over time are 
bypassing the knockout. Liver-to-body weight ratio in SRSF1 HKO do not show a 
significant difference in comparison to control. However, gonadal fat-to-body weight ratio 
shows significant reduction at both the 5 week and 3-month time point (Figure 2.7). 
Histological analysis at these later timepoints reveal development of NASH-like pathology 
such as inflammation and fibrosis (Figure 2.9). At the five-week timepoint, severe 
damage of the liver is seen from the H&E staining with infiltration of inflammatory cells 
and necrosis of hepatocytes. However, at later timepoints the inflammation and necrosis 
reduce. Oil Red O staining reveals lipid accumulation within the tissue at both 5 week and 
3-month timepoint, however, by 6 month the lipid levels decrease. Fibrosis is also present 
by 3 month and develops to bridging fibrosis by 6 months (Figure 2.9). 
2.3.3 Cell Death in SRSF1 HKO does not occur via Apoptosis 
Significant cell death is observed in SRSF1 HKO model at earlier timepoints. To 
determine if the cell death occurs via apoptosis, TUNEL staining was performed on tissue 
sections (Figure 2.10 C). SRSF1 HKO tissue sections do not show any TUNEL staining 
signifying hepatocytes do not undergo apoptosis. It is most likely that loss of SRSF1 




2.3.4 Repopulation of SRSF1 Expressing Hepatocytes in Adult SRSF1 HKO 
To evaluate the extent of repopulation of the liver with SRSF1 expressing 
hepatocytes at adult stages, IF analysis was performed at 5 weeks and 3 months 
timepoints (Figure 2.10 A). Quantification reveals that livers of SRSF1 HKO mice at 5 
weeks are still in the process of repopulating with nearly 60% of hepatocytes expressing 
SRSF1. This corroborates with the western blot analysis shown previously in Figure 2.6 
C. By 3 months, the tissue is completely repopulated by SRSF1 expressing hepatocytes 
(Figure 2.10 A). This repopulation is most likely a result of shutting off of Cre expression. 
To test this hypothesis, Cre expression was measured at both 5 weeks and 3 months 
using qRT-PCR analysis. Compared to controls (AlbCre +/-), SRSF1 HKO livers have a 
remarkable downregulation of Cre expression (Figure 2.10 B).  
2.3.5 SRSF1 HKO by 1.5 Years Develop Nodules and Severe Inflammation 
SRSF1 HKO mice aged to 1.5 years tend to develop growths on the liver (Figure 
2.11 A). Further inspection of these growths using histological analysis reveals there is a 
striking infiltration of inflammatory cells and leukocytes within the tissue. These 
infiltrations also correspond to the nodular growths on the tissue (Figure 2.11 B). This 
infiltration also extends from portal triads. This inflammation is comparable to the 
inflammation observed in autoimmune hepatitis. Further IF imaging was performed to 
determine if the observed damage is a result of SRSF1 deficiency. However, IF imaging 
reveals that 1.5-year-old SRSF1 HKO liver tissue still contain SRSF1 expressing 
hepatocytes (Figure 2.11 C). One possible explanation of the extensive inflammation 
observed in aged SRSF1 HKO is a result of some inherent viral infection present within 
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the mouse facility. However, if this were the case, frequency of inflammation should be 
equivalent between control and SRSF1 HKO mice. Another possible explanation for the 
inflammation is that SRSF1 HKO mice exhibit an increased propensity to develop an 
autoimmune reaction to the increased aneuploid hepatocytes. While it has not been 
shown that SRSF1 HKO exhibit an increase in the number of aneuploid hepatocytes, this 
is most likely the case based on previous reports and the loss of Cre expression. Further 
investigation is necessary to distinguish the cause of the increased inflammation in aged 
SRSF1 HKO mice.  
2.3.6 SRSF1 Levels are not Regulated by Hepatic Lipid Content 
To check if SRSF1 levels are regulated by hepatic lipid content, SRSF1 levels were 
measured in a steatosis model. Adult mice were fed a high-fat diet for 8 weeks to allow 
for the accumulation of lipids within the liver. Brief characterization of the model reveals 
that the mice develop severely fatty livers (Figure 2.12 A-C). This is evident from the 
gross images of the livers collected from this model after 8 weeks of high-fat diet 
treatment. Livers from the high-fat fed mice are strikingly yellow in appearance due to the 
significant buildup of lipids within the tissue (Figure 2.12 C). Western blot analysis 
performed on isolated hepatocytes show there is no significant change in SRSF1 in this 
hepatic steatosis mice model (Figure 2.12 D). With these findings, it can be concluded 




It is now well-known that post-transcriptional gene regulation contributes 
significantly to maintaining normal tissue physiology. To study the role of the prototypical 
splicing factor, SRSF1, within the liver, a hepatocyte specific SRSF1 knockout model was 
developed. Characterization of SRSF1 HKO mice early in development reveal robust 
accumulation of lipid within the liver (Figure 2.2 A and 2.3). This is followed by significant 
cell death, inflammation, and eventual development of fibrosis (Figure 2.9). The 
pathology seen in this model closely follows that of the human liver disease known as 
Non-alcoholic steatohepatitis. However, further inspection of the phenotype reveals that 
the liver damage observed in SRSF1 HKO is a result of continuous cell death and 
regeneration. This is evident from the immunofluorescent (IF) and western blot analysis 
performed on the tissue at various time-points in the SRSF1 HKO model. 
Immunofluorescent (IF) analysis on tissue sections showed the greatest knockout 
of SRSF1 in SRSF1 HKO mice occurs at post-natal day six. To circumvent the loss of 
SRSF1, the liver begins regenerating and repopulating with SRSF1 expressing 
hepatocytes as soon as post-natal day eight. This immediate repopulation of the liver with 
SRSF1 expressing cells demonstrates the necessity of SRSF1 for hepatocyte survival. 
Without SRSF1, hepatocytes cannot function properly and eventually die. Repopulation 
of the liver in this model is most likely a contribution from two separate sources; 1) the 
proliferation of the small fraction of hepatocytes which escaped knock-out of SRSF1 and 
2) transdifferentiation of biliary epithelial cells (BEC) into hepatocytes. However, most 
hepatocytes originating from transdifferentiating BECs would undergo knock-out of 
SRSF1 as the cell begins expressing Albumin along with the Cre recombinase. This cycle 
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of hepatocyte proliferation and cell death due to SRSF1 knock-out continues over a span 
of time until the tissue slowly repopulates itself with hepatocytes resistant to SRSF1 
knock-out. This is evident from the IF staining at later timepoints which show that the 
fraction of hepatocytes expressing SRSF1 is increasing with time. While this may seem 
unlikely, this type of phenomena has been previously described and is possible due to a 
unique feature of the liver (Duncan et al. 2012; Duncan 2013). 
One of the most remarkable and often overlooked attributes of the liver is that over 
half of the mature hepatocytes are aneuploid. While these mature hepatocytes exhibit 
multiple chromosomal gains and losses, these cells are functional and can undergo 
mitosis. It is hypothesized that this feature of the liver has evolved as an adaptive 
mechanism to hepatoxic stresses. The widespread genetic heterogeneity provides a 
fitness landscape allowing selection for the fittest hepatocytes to persist against various 
insults. Support for this hypothesis was eloquently demonstrated by Duncan et al., 
utilizing a genetic liver disease model for hereditary tyrosinemia type I (Duncan et al. 
2012). This model is deficient of fumarylacetoacetate hydrolase (FAH), a critical enzyme 
in the metabolism of tyrosine, which results in toxic accumulation of fumarylacetoacetate. 
However, buildup of this toxic metabolite can be prevented by loss of an upstream 
enzyme known as homogentisic acid dioxygenase (HGD). To test if the liver could utilize 
adaptive aneuploidy to resist injury, Duncan et al. cleverly developed mice deficient for 
FAH and heterozygous for a mutation in HGD. Remarkably, livers in these mice 
developed regenerating nodules enriched with hepatocytes exhibiting a loss of 
chromosome 16 which contains the locus for Hgd. Specifically, chromosome 16-specific 
aneuploidy was approximately found in 50 % of the hepatocytes making the mice resistant 
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to injury. Similarly, this phenomenon of adaptive aneuploidy is occurring within the SRSF1 
HKO to ensure survival of the liver. 
Parallels exist in the model used by Duncan et al. to investigate adaptive 
aneuploidy and the SRSF1 HKO model. While loss of the Hgd locus is protective in their 
model, loss of the AlbCre locus is protective in SRSF1 HKO. Loss of the Cre recombinase 
would prevent knock-out of SRSF1 and ensure survival of the hepatocyte. This is strongly 
supported by the results obtained from the SRSF1 IF staining of the liver tissue sections 
at various timepoints in the SRSF1 HKO (Figure 2.4 and 2.7). Repopulation of SRSF1 
expressing hepatocytes is seen as early as post-natal day eight and continues to slowly 
repopulate until it reaches completion by three months. Greatest knock-out is observed 
at post-natal day six, however, even at this timepoint there are a small fraction of 
hepatocytes which are expressing SRSF1. These are most likely aneuploid cells which 
are deficient of the AlbCre locus and begin to proliferate in the early stages to repopulate 
the tissue. However, to overcome the severe hepatocyte deficiency, BECs begin 
transdifferentiating into hepatocytes. This is evident from the SRSF1 IF staining in the 
SRSF1 HKO which show population of SRSF1 expressing cells in proximity to the portal 
triad. However, at the early timepoints most of these cells contain the AlbCre locus and 
will result in knock-out of SRSF1 and eventual cell death. This cycle will continue until the 
liver is primarily consists of aneuploid cells which lose expression of Cre and thus are 
able to express SRSF1. Indeed, measurement of Cre mRNA expression using qRT-PCR 
at 5 weeks and 3 months revealed significant reduction in Cre expression (Figure 2.10 
B). The chronic cycle of cell death and regeneration leads to the NASH-like pathology 
observed in this model. However, as the liver is repopulated with an increasing number 
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of SRSF1 knock-out resistant hepatocytes, the inflammation, damage, and lipid 
accumulation subside as well. Moreover, by eight weeks metabolic tests such as glucose 
tolerance test and fasting glucose levels do not show any significant differences between 
control and SRSF1 HKO mice (Figure 2.7 and 2.8).  
Finally, to confirm whether hepatic lipid content can regulate SRSF1 expression, 
levels of SRSF1 were checked in a diet induced steatosis mice model (Figure 2.12). Mice 
were put on a high-fat diet regime for eight months which resulted in significant 
accumulation of fat within the liver. Western blot analysis on hepatocytes isolated from 
these fatty livers shows that there was no difference in SRSF1 levels in comparison to 
the control chow-fed animals. We can therefore conclude that levels of SRSF1 in 
hepatocytes are not dynamically regulated by hepatic lipid content. To gain insight into 
the molecular mechanisms causing the pathology observed in SRSF1 HKO mice, RNA-









 SRSF1 HKO Mice Models Develop Steatosis  
(A) Gross images of the Control and SRSF1 HKO mice 10 days after birth. Development of 
severe steatosis is apparent at this timepoint. (B) Body weight measurements shows 
significant reduction in body weight in SRSF1 HKO (n = 6) (C) Abundance of SRSF1 was 
measured in hepatocytes from SRSF1 HKO. A significant reduction in SRSF1 abundance 





 SRSF1 HKO Livers Develop Severe Lipid Accumulation Early in 
Development 
To qualitatively assess the morphological changes within the tissue of SRSF1 HKO mice, 
both H&E and Oil Red O staining was performed. H&E staining allows for assessment of 






 SRSF1 HKO Livers Begin Repopulating with SRSF1 Expressing 
Hepatocytes Immediately After Knock-out 
To assess the extent of knockout both spatially and temporally in the SRSF1 HKO livers, 
immunofluorescence staining was used on tissue sections (n = 3, 6 fields) at various 
timepoints (SRSF1, green; HNF4a, red; Nuclei, blue). Immunohistochemical staining for 
ki67 was also performed at these timepoints to assess the extent of hepatocyte 




 Quantification of SRSF1 Expressing Hepatocytes and Proliferation at Early 
Timepoints 
Quantification of hepatocytes expressing SRSF1 (signal intensity > 10% of control levels) 








 Characterization of SRSF1 HKO Mice during Adult Development 
(A) Gross appearance of control and SRSF1 HKO mice and livers at 5 weeks and 6 months 
timepoint. Scale bar = 1 cm. (B) Body weight growth curve of controls and SRSF1 HKO 
mice. (C) Relative SRFS1 protein abundance quantification in SRSF1 HKO mice at 5 weeks 




 Liver- and Adipose-somatic index values for SRSF1 HKO mice 
Liver-to-body weight and Gonadal fat-to-body weight ratios in control and SRSF1 HKO 
mice during adult development. Liver-to-body weight ratios are not significantly different 
between control and SRSF1 HKO. However, gonadal fat-body weight ratio shows 




 Serum Metabolic Profile and Glucose Tolerance Test in SRSF1 HKO 
(A) Serum parameters in control and SRSF1 HKO mice during adult timepoints. ALT and 
AST show significant increase at earlier timepoints while cholesterol and triglycerides are 
significantly decreased at earlier timepoints. All parameters normalize by 6 months of age. 
Values are presented as mean + standard deviation. (B) Glucose tolerance test of control 




 Histology of SRSF1 HKO at Various Timepoints 
Histology of SRSF1 HKO at 5 weeks, 3 months, and 6 months. H&E shows inflammation at 
5 weeks. SRSF1 HKO have increased lipid accumulation at earlier timepoints. SRSF1 HKO 








 Regenerating SRSF1 HKO livers evade knockout by shutdown of CRE 
(A) SRSF1 expressing hepatocytes at 5 weeks and 3 months timepoint shows progressive 
repopulation. At 5 weeks nearly 60% of the hepatocytes are expressing SRSF1 with nearly 
complete repopulation by 3 months. (B) Expression of Cre by qRT-PCR shows significant 
reduction of levels in SRSF1 HKO. (C) SRSF1 HKO do not have any TUNEL staining 





 Characterization of 1.5-year-old SRSF1 HKO mice 
(A) Liver tissue from SRSF1 HKO develop growths on the liver (black arrow). (B) Histology 
of the tissue reveals severe infiltration of inflammatory cells into the tissue. (C) IF imaging 








 SRSF1 levels are not Regulated by Hepatic Lipid Accumulation 
A hepatic steatosis model was developed by feeding mice a high-fat diet. (A) After 8 weeks 
of feeding, mice were significantly heavier compared to controls. (B) High-fat diet mice 
have severe insulin resistance and (C) there is a striking accumulation of lipid within the 
tissue. (D) Western blot analysis on isolated hepatocytes from high-fat diet fed mice show 
no significant change in SRSF1 abundance.  
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Knocking out SRSF1 in hepatocytes results in severe accumulation of lipids within 
the tissue and widespread liver damage. SRSF1, originally discovered as a splicing 
factor, is known to regulate gene expression post-transcriptionally. Because of this 
activity, it was expected the pathogenesis observed is due to defects in the transcriptome. 
To gain better insight into the misregulation occurring within the transcriptome, RNA-Seq 
analysis was performed on purified hepatocytes. This approach allows for unbiased view 
of the transcriptome changes occurring in the SRSF1 HKO mice hepatocytes. 
Specifically, it provides information regarding both gene expression and splicing 
differences occurring in the mice model. Having a complete representation of these 
changes will help in elucidating the mechanisms causing immediate death of hepatocytes 
deficient of SRSF1. RNA-Seq was performed at 10 days and 5 weeks of age to allow for 





3.2 Material and Methods 
3.2.1 Isolation of RNA, Library Preparation and RNA-Seq 
Total RNA was prepared from frozen hepatocyte pellets using the RNeasy tissue 
mini-kit (Qiagen) following manufacturers protocol. Downstream RNA quality was 
assessed using an Agilent Bioanalyzer and quantified using a Qubit Fluorometer at the 
Roy J. Carver Biotechnology Center, UIUC. RNA-seq libraries were prepared and 100-
bp paired-end Illumina sequencing was performed on a HiSeq 4000 at the High 
Throughput Sequencing and Genotyping Unit, UIUC. 
3.2.2 RNA-Seq Analysis Workflow 
RNA-Seq reads were processed for quality and read length filters using 
Trimmomatic (version 0.38) (Bolger, Lohse, and Usadel 2014). For differential gene 
expression analysis, RNA-Seq reads were psuedoaligned using Kallisto (version 0.44.0) 
(Bray et al. 2016) (Figure 3.1). Transcript abundances were converted to gene 
abundances using tximport (version 1.11.7) (Soneson, Love, and Robinson 2015). With 
gene abundance tables, differential gene expression analysis was performed using 
DESeq2 (version 1.23.10) (Love, Huber, and Anders 2014). Differentially expressed 
genes were defined as having a |Log2(FoldChange)| > 1 and FDR < 0.05. For differential 
splicing analysis, RNA-Seq reads were mapped on the mouse genome (mm10) available 
on Gencode using STAR (version 2.4.2a) (Dobin et al. 2013). Alignment files were then 
used to perform differential splicing analysis using rMATS (version 3.2.5) and significant 
events were identified using imposed cutoffs (FDR < 0.10, junction read counts > 10, and 
deltaPSI > 15%) (Shen et al. 2014). Gene ontology analysis was performed using 
gProfiler and Enrichr (Raudvere et al. 2019; Kuleshov et al. 2016). Filtering and 
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3.3.1 Early and Late Gene Expression Changes in SRSF1 HKO Hepatocytes 
RNA-seq was performed on hepatocytes isolated from control and SRSF1 HKO at 
post-natal day 10 and 5-week timepoints to understand the early and late changes, 
respectively. Differential gene expression analysis reveals 1,825 and 1,902 genes 
changing in abundance at early and late stages, respectively (Figure 3.2). Furthermore, 
a larger fraction of differentially expressed genes (DEGs) are increasing in expression. 
Specifically, ~63% of DEGs are upregulated at the early timepoint whereas ~79% are 
upregulated at the late timepoints. DEGs overlapping between the early and late phases 
encompass 544 genes which corresponds to one-third of either gene set. In summary, 
loss of SRSF1 significantly impacts the hepatocyte transcriptome at both early and late 
stages of development. Furthermore, a large fraction of these changes persists through 
development as the hepatocytes struggle to resolve the irregularities resulting from 
SRSF1 deficiency. 
An interesting observation regarding the distribution of the overlapping gene set is 
that the fold change in abundance at the late phase tend be greater than the fold change 
during the early phase. This is apparent from the distribution of Log2(Fold Change) values 
(Figure 3.4). The Pearson correlation of the linear fit for the early and late overlap gene 
set is strong with a value of 0.647 and a 1:1 correlation with a slope of 0.938. However, 
the linear fit is shifted vertically up with an intercept of 0.988. This signifies that the 
changes in abundance are greater in the late phase when compared to the abundance 
change estimated at the early timepoint. This can further be demonstrated by the 
cumulative frequency plot of the differences in Log2(Fold Change) values between late 
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and early timepoints for the overlapping gene set (Figure 3.5). In comparison to the 
control set which consists of all expressed genes, the overlapping set is shifted to the 
right with a median difference of 0.648 which corresponds to a fold change of 1.56. 
Therefore, the genes that are upregulated in the early timepoint are further potentiated in 
expression at the later timepoint. 
3.3.2 Gene Ontology Analysis for Differentially Expressed Genes in SRSF1 HKO 
It is evident that substantial alterations to the transcriptome are triggered in 
response to SRSF1 ablation. It can be hypothesized that these changes are induced to 
resolve or compensate the irregularities caused by the deficiency of SRSF1 activity. To 
gain an understanding into what biological processes the DEGs are involved with, a gene 
ontology analysis was performed (Figure 3.3). The analysis was divided by the genes 
changing in expression at each timepoint and the direction of the change in abundance. 
Gene ontology analysis was performed using Enrichr and the results are represented in 
a bar plot with each GO term plotted with its Combined Score. Larger combined score 
values correspond to stronger enrichment of the GO term. 
Upregulated genes at the early and late timepoints enriched for terms involved in 
separate processes. For genes upregulated during the early SRSF1 HKO timepoint 
enriched for processes involved in inflammation with terms such as ‘positive regulation of 
chemotaxis’ and ‘chemokine-mediated signaling pathway’. This is not unexpected since 
knockout of SRSF1 results in immediate death of the cell as seen previously. It is known 
that widespread cell death triggers an inflammatory response to mediate recruitment of 
cells for repair of the tissue (Rock and Kono 2008). However, genes upregulated at the 
late timepoint enrich for processes involved in mitosis. This result agrees with the 
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phenotypic characterization of this model. At the 5-week timepoint, the SRSF1 HKO are 
still in the process of repopulating the tissue with hepatocytes that have shutdown Cre 
expression and can express SRSF1. As the tissue continues to repopulate, the 
inflammation subdues and proliferation increases. Biological processes that are shared 
at both timepoints are involved in wound healing and repair. 
Downregulated genes enrich for processes involved in metabolism at both 
timepoints. However, each timepoint is downregulated for a specific aspect of 
metabolism. Genes downregulated at the early timepoint are involved in sterol transport 
and fatty acid oxidation pathways. Whereas genes downregulated at the late stage 
encompass sulfur amino acid, ornithine, and urea metabolism. These differences in 
metabolic processes are most likely driven by differences in metabolism of normal livers 
as it matures.  
3.3.3 Inflammation and Wound Healing Signatures in SRSF1 HKO Hepatocytes 
Histological characterization of SRFS1 HKO mice livers across developmental 
stages shows significant damage of the tissue. Earlier stages are predominated by 
inflammation and cell damage. However, with time the inflammation subdues, and fibrosis 
occurs as scar tissue develops. To see if these findings are corroborated by gene 
expression profiles, levels of various inflammatory and fibrosis markers were examined 
from RNA-seq (Figure 3.6). In agreement with phenotypic characterization, inflammatory 
genes are primarily upregulated in the 10-day timepoint while fibrotic signature is 




3.3.4 Differential Splicing of Exons in SRSF1 HKO Hepatocytes  
Due to SRSF1’s role as a splicing factor, it is expected that loss of activity will result 
in defects in splicing of exons. To further gain insight into the splicing misregulation, 
differential splicing analysis was performed on the RNA-seq data using the well-
established rMATS package. Performing this analysis on the 10-day and 1-month 
timepoint datasets revealed 852 and 765 differentially spliced events, respectively 
(Figure 3.7 A). The overlap between these two sets consist of 216 splicing events. The 
splicing events are further sub-divided by the type of alternative splicing event which 
includes skipped exon (SE), mutually-exclusive exon (MXE), retained intron (RI), 
alternative 5’ splice site (A5SS), and alternative 3’ splice site (A3SS). At both timepoints, 
the SE event type had the largest representation of differentially spliced exons (Figure 
3.7 B). Furthermore, loss of SRSF1 resulted in over two-thirds of exons with decreased 
inclusions (Figure 3.9 A). This is expected as SRSF1 is known to promote the inclusion 
of exons. The differentially spliced events which were detected at both timepoints had 
very similar distributions. This can be seen in the distribution of ΔPSI values of the 
overlapping events. The correlation of the linear fit is strong with a slope of 0.856. 
Furthermore, the distribution of the difference of the ΔPSI (ΔΔPSI) are mostly centered 
around zero (Figure 3.9 B).  
3.3.5 Gene Ontology Analysis for Differentially Spliced Exons in SRSF1 HKO 
In comparison to the gene ontology analysis performed on the differential gene 
expression dataset, the analysis for differential splicing showed weaker enrichment 
scores. Genes with differentially spliced exons at the 10-day timepoint enriched for 
processes involved in DNA damage while the 1-month timepoint enriched for processes 
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involved in nuclear protein localization and RNA destabilization (Figure 3.10 A). Genes 
that shared differentially spliced exons at both timepoints enriched for terms involved in 
wound healing and regulation of signaling cascades (Figure 3.10 B). 
3.3.6 Overlap of Differential Expression and Splicing in SRSF1 HKO 
To examine if the changes in gene expression and splicing are dependent 
processes, overlap of these two datasets at each timepoints was determined. For 
example, if splicing has a significant effect on steady state gene abundance, it would be 
expected that a significant overlap of the two sets be present. Overlap of gene expression 
and splicing showed a total of 72 and 78 genes at the 10-day and 1-month, timepoints 
(Figure 3.11). Furthermore, the overlap p-values at both timepoints showed that the 
overlap was not significant (overlap p-value < 0.477 and < 0.275 at 10-day and 1-month, 
respectively). Therefore, this suggests that changes in splicing and gene expression are 




RNA-Seq analysis of SRSF1 HKO mice at both ten-day and 1-month timepoints 
provide rich information regarding changes in gene abundances and exon usage 
occurring in the model. It is apparent that loss of SRSF1 activity in hepatocytes results in 
substantial changes to the SRSF1 HKO transcriptome. It should be noted, however, that 
phenotypic characterization showed that by post-natal day 10, significant liver damage 
and hepatic cell death has already occurred. Therefore, the changes that are detected in 
the transcriptome are most likely a result of secondary effects of SRFS1 ablation. 
Deficiency of hepatic activity triggers immediate regenerative response as early as 10 
days. This is further corroborated with the gene expression signatures seen in the 10-day 
RNA-seq. Namely, an enrichment for processes involved in inflammation is seen in the 
upregulated gene set. This response is expected as widespread cell death will inevitably 
trigger an inflammatory response (Rock and Kono 2008). However, as the liver continues 
to regenerate it spontaneously repopulates with SRSF1-expression hepatocytes as it 
gains the ability to suppress Cre expression. At later timepoints, the inflammation 
reduces, and further expansion of the SRSF1-expressing hepatocytes predominates to 
compensate for the required hepatic functionality. Indeed, by the later 1-month timepoint, 
a strong enrichment for genes involved in mitosis and cell cycle processes are enriched 
(Figure 3.3).  
As expected, due to the widespread damage and loss of hepatocyte functions, a 
strong decrease in metabolic capacity is seen in the SRSF1 HKO. Interestingly, each 
timepoint exhibits a downregulation a specific aspect of metabolism. Specifically, early 
timepoint shows downregulation of genes involved in fatty acid metabolism whereas late 
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timepoint shows downregulation of amino acid, ornithine, and urea cycle metabolism. A 
possible explanation for this difference is that it is driven primarily by the difference of the 
metabolic gene profile during liver development. As the liver matures, there is activation 
of mature metabolic functions including amino acid and urea cycle metabolism. Therefore, 
metabolic genes in general are downregulated in SRSF1 HKO due to the widespread 
damage response.  
Overall, the RNA-seq data at these two timepoints further support the pathology 
observed in the SRSF1 HKO mice. These mice exhibit significant inflammation at early 
stages which decreases with time as the tissue repopulates with SRSF1-expressing 
hepatocytes. At later stages, development of scar tissue is observed with the 
development of fibrosis. Indeed, these signatures are also seen from gene expression 
analysis at the early and late timepoints. Specifically, inflammatory signature is activated 
at the 10-day timepoint with fibrotic signature primarily upregulated at the 1-month 
timepoint (Figure 3.6). Due to the immediate damage response, to gain better insight into 
the mechanism of pathogenesis, a model allowing for improved temporal control of 
SRSF1 ablation will provide opportunity to isolate hepatocytes before secondary changes 
occur.   
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 Breakdown of Early and Late Gene Expression Changes in SRSF1 HKO 
A Venn diagram summarizing the number of genes changing in expression in hepatocytes 
of SRSF1 HKO at both early and late stages of development. A total of 1825 and 1902 genes 
are changing in expression (Log2 Fold Change > 2 and FDR < 0.1) at early and late stages, 





 Scatter Plot of Expression Fold Changes of Early and Late Stages 
Scatter plot of gene expression fold change values at both 10 days and 1-month 
timepoints. Significant number of genes expression changes are specific to each 
timepoint. A strong positive correlation is seen for genes that are found to be changing at 






 Cumulative Plot of Fold Change Differences for Differentially Expressed 
Genes in Late and Early Timepoints  
Cumulative plot of fold change differences for genes differentially expressed in early and 
late timepoints (red line). The Control plot (black line) corresponds to fold change 
differences for all expressed genes between both timepoints. The cumulative plot of the 
overlap differences is right shifted, signifying that for genes found to be differentially 





 Gene Ontology Analysis of Differentially Expressed Genes in SRSF1 HKO 
Gene ontology analysis of differentially expressed genes during early and late timepoints. 
Genes upregulated during early timepoints enrich for inflammatory processes while genes 
activated at late timepoints enrich for cell cycle and mitotic processes. During both 









 SRSF1 HKO Hepatocytes Transition from an Inflammatory to Fibrotic 
Response with Development 
Plot of fold change values for genes involved in inflammation and fibrosis at both early 
(yellow bars) and late (red bars) timepoints. At early timepoints, a larger fraction of genes 
involved in inflammation are induced. While genes involved in fibrosis are more strongly 






 Differential Splicing during Early and Late Stages of SRSF1 HKO 
(A) Venn diagram depicting the total number of exonic events with significant differential 
splicing (ΔPSI > 0.15, FDR < 0.10) between control and SRSF1 HKO mice at 10 days and 1-
month timepoints. A percent overlap of about 20.2% and 22.0% was found between 10 days 
and 1-month SRSF1 HKO, respectively. (B) Breakdown of the number of differentially 
spliced exons by event type. A greater proportion of events showed decreased inclusion 






 Scatter Plot of ΔPSI of Exons at Early and Late Stages of SRSF1 HKO 
Scatter plot of ΔPSI values for all significantly changing splicing events in either 10 days 
or 1-month SRSF1 HKO timepoints. Red points depict events which are specifically found 
to be changing at early stages while blue points are events which are late stage specific. 
Green points are events which are differentially spliced in both stages. Overlapping events 







 Distribution of ΔPSI values at Early and Late SRSF1 HKO Timepoints 
(A) Violin plot depicting distribution of ΔPSI values for all significant differentially spliced 
events at each timepoint. Green highlighted distribution signifies the differential exon 
events that are present in both timepoints. The distributions are not significantly different, 
and both have greater proportion of exons being excluded with SRSF1 knockout. (B) Violin 
plot depicting distribution of ΔPSI differences (ΔΔPSI) of overlapping events in early and 
late stages. All events type distributions are primarily centered at zero and thus showing 






 Gene Ontology Analysis of Genes with Differential Splicing at Early and Late 
Timepoints in SRSF1 HKO Mice 
(A) Gene ontology analysis of genes with differential splicing events at both early and late 
timepoints in SRSF1 HKO hepatocytes. Early phase genes with differential splicing are 
enriched for processes involved in DNA damage response and repair. While in the late 
phase, genes with differential splicing enrich for processes involved in nuclear protein 
organization and RNA destabilization. (B) GO terms for genes that are differentially spliced 







 Genes with Differential Expression and Splicing in SRSF1 HKO for each 
Timepoint 
Venn diagrams depicting overlap of genes changing in expression and splicing for each 
timepoint. The overlap in each set is not significant (overlap p-value > 0.05) and thus 




 Elucidating Early Changes in Hepatocytes After 
Acute Ablation of SRSF1 
 
4.1 Introduction 
From Chapters 2 and 3, it is apparent that loss of SRSF1 within hepatocytes is not 
well tolerated and results in cell death. However, due to the high regenerative capacity of 
the liver, the tissue can subvert the knockout of SRSF1. This is most likely achieved 
through mechanisms such as transdifferentiation of BECs or asymmetric proliferation of 
hepatocytes resulting in aneuploid cells deficient of the Cre transgene. Repopulation of 
the liver with SRSF1 expressing hepatocytes is observed as early as eight days after 
birth. This aspect of the SRSF1 HKO model poses difficulty in elucidating the mechanism 
of pathogenesis, namely, the significant accumulation of lipids within the tissue and 
subsequent cell death. To circumvent this issue, an acute hepatocyte-specific SRSF1 
knockout model (acSRSF1 HKO) was developed. This was achieved by using adeno-
associated viral vectors expressing the Cre recombinase driven by a hepatocyte-specific 
promoter. This ensures that knockout of SRSF1 occurs only within hepatocytes. The 
acSRSF1 HKO allows for improved temporal control and studying of early changes 
occurring in the tissue upon loss of SRSF1. The acSRSF1 HKO allows for the isolation 
of SRSF1 deficient hepatocytes prior to any development of severe pathology. This model 
provides the ability to tease out the chain of events triggered by the loss of SRSF1 which 
results in the eventual death of the cell.  
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4.2 Material and Methods 
The following sections provides details of the materials and methodology utilized 
for the studies performed in this chapter. For details on additional methodology refer to 
Section 9.1: Supplementary Protocols. 
4.2.1 Generating Acute Hepatocyte-Specific SRSF1 Knock-out Mice Model 
Mice with floxed alleles for SRSF1 were injected with adeno-associated viral 
vectors (VectorBio Labs) either expressing GFP (Controls) or the Cre recombinase 
(acSRSF1 HKO) from the thyroxine binding globulin (TBG) promoter which is hepatocyte 
specific. Mice were injected at 8 weeks of age with a titer of 5 x 1011 gc via the tail vein. 
The mice were housed on a standard 12-hour-light/dark cycle and fed a normal chow diet 
(2918 Envigo Teklad). The mice were fasted for 6 hours prior to harvesting tissues for 
subsequent analysis. Tissue harvesting was performed at 2- and 4-weeks post-injection. 
Hepatocytes were isolated only after 2 weeks. National Institutes of Health (NIH) 
guidelines for use and care of laboratory animals was followed and all the experiments 
were approved by the Institutional Animal Care and Use Committee at the University of 
Illinois at Urbana-Champaign.  
 




4.2.2 Lipid Isolation from Liver Tissue 
Lipids were extracted from approximately 100 mg of liver tissue using the Folch 
Method (Folch, Lees, and Sloane 1957). Briefly, the tissue was homogenized in 1 mL of 
2:1 choroform:methanol mixture. The homogenized mixture was incubated overnight at 
room temperature to allow for complete extraction. The mixture was then centrifuged at 
10,000 x g for 10 minutes to pellet any debris. The supernatant was transferred to a fresh 
tube. The interface was washed with 1 X PBS solution to remove any additional salt. The 
mixture was centrifuged at 4,000 x g and aqueous layer was removed. The organic phase 
was dried under nitrogen stream and then reconstituted in 300 µL of ethanol. The 
reconstituted mixture was used with Infinity Kit to determine concentrations of 
triglycerides and cholesterol. 
4.2.3 Serum Chemistry Analysis 
Serum chemistry measurements were performed in both control and acSRSF1 
HKO mice at 2- and 4- weeks post viral injections. Mice were fasted for 6 hours (noon to 
6 p.m.) before collecting blood. Blood was collected as specified in Section 2.2.2, followed 
by flash freezing of the serum in liquid nitrogen. Frozen serum samples were submitted 
to the Mouse Metabolic Phenotyping Core at the University of Cincinnati. A clinical 
chemistry analyzer was used to measure concentration of the following serum 
components, triglycerides, cholesterol, phospholipids, non-esterified fatty acids, glucose, 






4.3.1 Acute Hepatocyte-Specific Knockout of SRSF1 Results in Severe Steatosis  
Using the AAV8-TBG-iCre vector, robust hepatocyte-specific knockout of SRSF1 
was achieved. By 2-weeks post-viral transduction, near complete loss of SRSF1 
expression can be seen by western blot analysis (Figure 4.2 B).  At this timepoint, gross 
inspection of the liver shows mild changes in appearance corresponding to mild steatosis. 
However, by 4-weeks, the acSRSF1 HKO livers are notably yellow in color throughout 
the whole liver signifying severe steatosis (Figure 4.2 A). Serum collected at this 
timepoint is also strikingly golden in color which is most likely due to increased bilirubin 
levels (Figure 4.2 C). Furthermore, weekly assessment of body weight changes in the 
acSRSF1 HKO model shows that these mice maintain their body weight until 3-weeks 
post viral transduction at which point the mice begin to drastically lose weight. By 4-weeks 
the acSRSF1 HKO mice lose on average about 15% of their body weight (Figure 4.3). 
4.3.2 Eventual Repopulation of Liver with SRSF1 Expressing Hepatocytes 
Interestingly, SRSF1 western blot analysis at the 4-week timepoint shows 
increased levels of SRSF1 in comparison to the 2-week timepoint (Figure 4.2 B). To 
determine if these increased levels are due to infiltration of the tissue with inflammatory 
cells or repopulation with SRSF1-expressing hepatocytes, immunofluorescent co-staining 
for SRSF1 and HNF4α was performed on tissue sections (Figure 4.4 A). The fluorescent 
images from acSRSF1 HKO reveal that there is repopulation of the tissue with SRSF1-
expressing hepatocytes. This expansion also appears to originate from the portal triad 
region. To assess for apoptosis in the acSRSF1 HKO model, TUNEL staining was 
performed which were negative at both timepoints (Figure 4.4 B).  
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4.3.3 Histological Analysis Reveals Hepatocyte Necrosis in acSRSF1 HKO 
To gain insight into the pathological changes occurring at the level of tissue 
architecture, histological staining of tissue sections was performed. H&E, Oil Red O and 
Sirius Red staining were performed on tissues collected from control and acSRSF1 HKO 
mice at the 2- and 4-week timepoints. At the 2-week timepoint, the tissue is beginning to 
show lipid accumulation with microsteatosis occurring near central vein hepatocytes or 
Zone 1. At this timepoint minimal damage is observed in the tissue architecture with no 
development of fibrosis as seen by the absence of staining in Sirius Red. However, by 4 
weeks, Oil Red O staining shows significant limpid accumulation with macrosteatosis 
present within all zones of the tissue. Furthermore, H&E staining shows ballooned 
hepatocytes which suggest necrotic cell death. Similar to the 2-week timepoint, no 
scarring of the tissue is observed. 
4.3.4 Loss of SRSF1 Leads to Decreased Levels of Hepatic Cholesterol 
Gross inspection of the tissue shows that the acSRSF1 HKO model develop 
severe steatosis. However, it is not apparent whether this accumulation of lipids is due to 
triglycerides or cholesterol. To answer this question, total lipids was extracted from the 
tissue using the Folch method followed by quantification of triglycerides and cholesterol 
levels normalized to the tissue mass. This assay was performed in controls and 
acSRFSF1 HKO at both 2- and 4-week timepoints. The quantification results of the 
hepatic triglycerides and cholesterol show that the composition of the accumulated lipid 
are triglycerides (Figure 4.6). The triglycerides progressively increase in concentration 
with time which agrees with the gross appearance noted of the liver. Interestingly, hepatic 
cholesterol levels are diminished in acSRSF1 HKO. 
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4.3.5 AcSRSF1 HKO Experience Depletion of Adipose Stores 
Characterization of the acSRSF1 HKO mice reveals striking lipid accumulation 
within the liver tissue and significant loss in total body weight. To gain additional insight 
into the state of both liver and adipose tissues in acSRSF1 HKO, liver and gonadal 
adipose tissues were weighed and normalized to total body weight at each timepoint 
(Figure 4.7). As expected, liver weight normalized to body weight progressively increase 
as the tissue accumulates lipids. Interestingly, on the other hand, adipose tissue shows 
a striking decrease in normalized weights. At the 4-week timepoint, there is nearly 
complete loss of the gonadal adipose tissue stores. 
4.3.6 Serum Profiling Reveals Loss of Hepatic Function in acSRFS1 HKO 
The liver plays a major role in maintaining levels of multiple metabolites within the 
serum. Understanding how the serum is affected in the acSRSF1 HKO will provide better 
grasp of the deficiencies caused by loss of SRSF1 activity. To this end, serum profiling 
was performed on 6-hour fasted control and acSRSF1 HKO mice at each timepoint 
(Figure 4.8). Overall, 2-week acSRSF1 HKO do not show any significant differences of 
any serum parameters. This provides support that significant damage and secondary 
effects have not yet occurred in this model. However, by 4 weeks, acSRSF1 HKO mice 
show significant elevation in ALT and AST levels signifying severe liver damage. With 
regards to fasting glucose levels, 4-week acSRSF1 HKO maintain a level around 65 
mg/dL which is significantly decreased in comparison to controls. Furthermore, ketone 
bodies are also strikingly diminished at the 4-week timepoint. Finally, serum cholesterol 
and phospholipid levels show progressive decline in concentration. Triglycerides and 




Due to the immediate liver damage that is triggered in the SRSF1 HKO mice, the 
acSRSF1 HKO mice was developed. In this model, knockout of SRSF1 is induced by 
transduction of an AAV vector expressing the Cre transgene into SRSF1 floxed mice. 
This provides further temporal control of over the knockout of SRSF1. Furthermore, this 
knockout is hepatocyte-specific as the Cre transgene is driven by the hepatocyte-specific 
TBG promoter. The temporal control of SRSF1 knockout allows for isolation of 
hepatocytes before severe damage and secondary effects are triggered. However, before 
any molecular studies can be performed, a thorough phenotypic characterization of the 
model is necessitated. The first insight this model provides is whether the damage 
observed in SRSF1 HKO dependent on the developmental stage at which the knockout 
occurs. It will also reveal if knocking out SRSF1 in hepatocytes in adult livers phenocopy 
the SRSF1 HKO mice which experience knockout at post-natal day 6. Indeed, knocking 
out of SRSF1 in adult mice livers resulted in severe steatosis and liver damage as 
observed in the SRSF1 HKO mice (Figure 4.2 and 4.5). Interestingly, however, the 
acSRSF1 HKO appear to develop the pathology at a slower rate as compared to the 
SRSF1 HKO model. For instance, in the SRSF1 HKO model, knockout is observed at 
post-natal day 6 with significant steatosis within 4 days at post-natal day 10. In the 
acSRSF1 HKO, knockout is observed at 2 weeks with significant steatosis and damage 
occurring at 4 weeks. It should be mentioned that intermediate timepoints were not 
collected for the acSRSF1 HKO, therefore, the exact timing at which pathology develops 
in acSRSF1 HKO mice cannot be determined. However, the extent of repopulation with 
SRSF1-expressing hepatocytes at 4 weeks is comparable to what is seen at the 10-day 
SRSF1 HKO mice (Figure 4.4). Furthermore, the weights of acSRSF1 HKO mice are 
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stable until 4-weeks at which a significant drop is observed (Figure 4.3). Taking this 
together, the development of pathology in the acSRSF1 HKO mice appear to be delayed 
in comparison to SRSF1 HKO. A possible explanation of this observation is due to the 
developmental timing at which the knockout occurs. In SRSF1 HKO, the knockout occurs 
at an early timepoint in which hepatocytes are highly proliferative and in the process of 
remodeling as it transitions from a fetal to mature state. However, in acSRSF1 HKO the 
knockout out occurs in adults where the hepatocytes are fully mature and quiescent.  
Like the SRSF1 HKO model, the acSRSF1 HKO mice also exhibit repopulation of 
the tissue parenchyma with SRSF1-expressing cells seen at the 4-week timepoint 
(Figure 4.2 A). This is expected, as the liver is known to be highly regenerative and can 
replace the dying hepatocytes. However, unlike the SRSF1 HKO mice which 
spontaneously generate hepatocytes deficient of the Cre transgene, the acSRFS1 HKO 
mice repopulate with SRSF1-expressing hepatocytes most likely through 
transdifferentiation of BECs where SRSF1 is intact. This can be seen from the fluorescent 
imaging which shows SRSF1-expressing hepatocytes originating from the portal triad 
region (Figure 4.4 A).  
It is evident that ablation of SRSF1 hepatocytes is resulting in eventual death of 
the cell. This can be seen from the severely elevated serum ALT and AST levels in 
acSRSF1 HKO which is a marker of liver damage (Figure 4.8). Therefore, it should be 
expected that widespread loss of hepatocyte activity will result in hepatic failure. Indeed, 
the phenotypic characterization of this model supports this reasoning. Fasting serum 
levels of glucose and ketone bodies at 4-weeks show striking evidence of hepatic failure. 
The acSRSF1 HKO mice have decreased fasting blood glucose levels due to the failure 
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in gluconeogenesis that is required to maintain fasting levels. Furthermore, under fasting 
conditions when glycogen stores are depleted, the liver tissue begins generating ketone 
bodies as an alternative fuel source from the metabolism of fatty acids. The liver is the 
only tissue that can generate ketone bodies. In the acSRSF1 HKO mice, ketone bodies 
are also severely diminished during the fasting state which further supports that loss of 
SRSF1 results in hepatocyte death and liver failure.  
The liver also plays a major role in lipid and steroid metabolism. Under normal 
physiological conditions, the liver is involved in packaging lipids into lipoprotein particles 
for systemic delivery as well as synthesis of cholesterol for the body. It is evident that loss 
of SRSF1 results in severe accumulation of lipids within the tissue. Furthermore, there is 
a striking decrease in adipose tissue stores in acSRSF1 HKO mice (Figure 4.7). This is 
most likely due to deficiency of hepatic function and failure to generate lipoprotein 
particles for systemic delivery of fatty acids. This signals the peripheral adipose stores to 
mobilize fatty acids into circulation for uptake and packaging by the liver. However, due 
to the failure of hepatocytes in acSRSF1 HKO, this results in a futile cycle in which fatty 
acids are being sent to the liver where it accumulates. This is supported by the normalized 
weights of the liver and adipose tissue seen in this model which shows increased liver 
weight ratios with subsequent decrease in adipose weight ratios (Figure 4.7). The liver 
also plays a major role in synthesizing cholesterol for the body. Additionally, hepatic and 
serum cholesterol levels are diminished in the acSRSF1 HKO. In conclusion, acute loss 
of SRSF1 results phenocopies the pathologies observed in SRSF1 HKO and that loss of 
SRSF1 results in death of hepatocytes leading to liver failure.  
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 Acute Knockout of SRSF1 Recapitulates SRSF1 HKO Phenotype 
(A) Gross images of livers from SRSF1 flox/flox mice 2- and 4-weeks post injection with 
AAV8-TBG-GFP (Controls) or AAV8-TBG-iCre (acSRSF1 HKO). At 2 weeks, acSRSF1 HKO 
livers are starting to become steatotic. However, at 4 weeks, acSRSF1 HKO livers exhibit 
severe steatosis with yellow appearance. (B) Western blot showing SRSF1 levels in 
acSRSF1 HKO. As expected, 2-week mice show complete loss of SRSF1. However, by 4 
weeks, acSRSF1 HKO hepatocytes show significant expression of SRSF1 signifying 
repopulation of the tissue with SRSF1 expressing hepatocytes. (C) Pictures of serum 
isolated from control and acSRSF1 HKO mice at 4 weeks. The acSRSF1 HKO mice have 









 Acute SRSF1 HKO Mice Exhibit Drastic Loss of Total Body Weight  
Plot showing weekly changes in body weights with respect to initial weight of Control and 
acSRSF1 HKO post viral induction. AcSRSF1 HKO exhibit a drop in body weight at 3 weeks 
followed by drastic decrease in body weight at 4 weeks. Acute SRSF1 HKO mice have an 





 Eventual Repopulation of SRSF1 Expressing Hepatocytes in acSRSF1 HKO 
(A) Immunofluorescence staining for SRFS1 in acSRSF1 HKO mice at 2- and 4-weeks post 
viral induction. At 2 weeks, effective knockout of SRSF1 is achieved shown by no SRSF1 
signal in hepatocyte nuclei. By 4 weeks, SRSF1 expressing hepatocytes are beginning to 
repopulate the tissue as seen by the yellow colored nuclei. These SRSF1 expressing 
hepatocytes originate from the portal triad region. This result agrees with the western 
analysis showing re expression of SRSF1 at the 4-week timepoint. (B) TUNEL staining of 
acSRSF1 HKO at 2- and 4-weeks. Staining are negative signifying that these cells do no 






 Histological Analysis of acSRSF1 HKO at 2- and 4-week Timepoints 
To gain insight into the morphological changes within the tissue of acSRSF1 HKO mice, 
H&E, Oil Red O, and Sirius Red staining were performed. Representative image of each 
staining for each group at each timepoint are shown (n = 4-5 per group). H&E staining at 2 
weeks shows overall tissue architecture is intact with evidence of steatosis. By 4 weeks, 
the tissue architecture is drastically altered with ballooning cell death. Oil Red O staining 
shows progressive accumulation of lipids within acSRSF1 HKO livers which agrees with 









 Hepatic Triglycerides and Cholesterol Levels in acSRSF1 HKO Mice 
Box plots of hepatic triglyceride and cholesterol levels at 2- and 4-week post viral induction 
timepoints in acSRSF1 HKO mice (n = 6 – 8 mice per group). AcSRSF1 HKO exhibit 
progressively increasing levels of hepatic triglycerides while cholesterol levels are 
decreased at both timepoints. Two-way ANOVA statistical test was used to determine 








 Liver- and Fat-to-Body Weight Ratio in AcSRSF1 HKO Mice 
Liver weight and gonadal fat weight normalized to total body weight at 2- and 4-week post 
viral induction timepoints in acSRSF1 HKO mice (n = 6 – 7 mice per group). AcSRSF1 HKO 
exhibit elevated liver-to-body weight ratios at both timepoints. However, gonadal fat-to-
body weight ratios are significantly decreased at 4 weeks in acSRSF1 HKO mice. Two-way 
ANOVA statistical test was used to determine significance between 2 groups at 2 






 Serum Profiling in acSRSF1 HKO Mice Reveal Striking Liver Damage 
Serum profiling of multiple serum parameters in 6 hours fasted acSRSF1 HKO mice at both 
2- and 4-week timepoints. No significant change is seen in any serum parameter at 2-
weeks. By 4 weeks, acSRSF1 HKO exhibit significant liver damage as seen by elevated 
AST and ALT levels. Furthermore, fasting ketone bodies and cholesterol levels are 
significantly decreased showing diminished hepatic functionality. Two-way ANOVA 
statistical test was used to determine significance between 2 groups at 2 timepoints. *P < 
0.05, **P < 0.01, ***P < 0.001.  
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 Loss of SRSF1 Results in R-Loop Accumulation 
and Widespread DNA Damage 
 
5.1 Introduction 
Acute hepatic knockout of SRSF1 results in robust accumulation of lipids within 
the cells. The acute model recapitulates the pathology observed with the transgenic 
model, SRSF1 HKO. While severe steatosis is observed by post-natal day 10 in SRSF1 
HKO, it takes four weeks to develop steatosis to similar levels in the acSRSF1 HKO. This 
delayed response in acSRSF1 HKO is most likely due to the difference in developmental 
timepoint at which the knockout occurs. At early stages, the liver is highly dynamic as it 
is transitioning from a fetal to a mature state. However, in the acSRSF1 HKO model, 
knockout is induced in adult livers which consist of fully matured and quiescent 
hepatocytes. This delayed pathological development provides opportunity to capture 
SRSF1 deficient hepatocytes before secondary changes begin to take place. 
To determine early changes occurring within this model, RNA-Seq was performed 
two weeks post viral mediated knockout. At this timepoint, robust knockout of SRSF1 has 
been achieved, however, severe pathological changes have not yet developed. In 
addition to RNA-seq analysis, an eCLIP-seq for SRFS1 was performed in adult wildtype 
mice. This technique allows for the determination of direct mRNA targets of RNA binding 
proteins at the single nucleotide resolution. The goal of performing eCLIP-seq was to 
further aid in understanding the primary mechanism resulting in development of the 
observed pathology Specifically, the transcriptome changes determined from RNA-seq 
can be cross referenced with the eCLIP-seq binding data to identify key players.  
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5.2 Material and Methods 
The following sections provides details of the materials and methodology utilized 
for the studies performed in this chapter. For details on additional methodology refer to 
Section 9.1: Supplementary Protocols. 
5.2.1 RNA-Seq Analysis of acSRSF1 HKO Mice Model 
RNA-Seq analysis was performed on isolated hepatocytes from 2-week control 
and acSRSF1 HKO mice (n = 3 per group) as described in Section 3.2.1. The data was 
analyzed using workflow described in Section 3.2.2. 
5.2.2 eCLIP-seq Library Preparation, Sequencing, and Data Processing  
Hepatocytes were isolated from livers using the Two-Step Collagenase Perfusion 
technique as described in Section 9.1.2. Isolated hepatocytes suspended in PBS were 
then exposed to 400 mJ/cm2 of 254 nm UV radiation to crosslink and stabilize RNA 
binding protein (RBP)–RNA interactions. Subsequent immunoprecipitation of SRSF1-
RNA complexes, RNA isolation, library preparation and sequencing were performed as 
previously described (Van Nostrand et al. 2016). Raw reads were mapped to the mm9 
mouse genome using STAR and peak calling was performed using the publicly available 
tool CLIPper (https://github.com/YeoLab/clipper). This tool provided identified peaks in a 
BED12 format. This data was further processed and analyzed using custom python and 
R scripts. 
5.2.3 Dot Blot Assays for DNA-RNA Hybrid and PolyA mRNA 
DNA-RNA hybrid dot blot assay was adapted from a previously published report 
(Morales et al. 2016). Briefly, DNA was isolated from approximately 50 mg of liver tissue 
or snap frozen cells using DNeasy Blood & Tissue Kit (Qiagen) using the manufacturer’s 
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protocol. For each sample 250 ng of DNA was digested with 5 Units of RNase H (NEB) 
as control. The slot blot apparatus was setup by placing 2 layers of filter paper soaked in 
PBS with a HybondTM-N+ membrane (Amersham) layered on top before clamping down 
the well block. 250 ng of DNA was diluted with PBS to 200 µL and then transferred to the 
apparatus well. Vacuum suction was applied to the apparatus outlet to allow for suctioning 
of well volume through the membrane layers. The membrane was then auto cross-linked 
with UV (254 nm, 1200 mJ/cm2). The membrane was then air-dried before beginning 
blocking with 5% nonfat dry milk and 0.1% Tween 20 (TBST). Membrane was then 
incubated overnight at 4°C with S9.6 antibody diluted in blocking buffer. Finally, it was 
probed with Mouse-HRP secondary antibody and developed as described in Section 
9.1.3. Refer to Section 9.1.9 for details on antibody source and dilutions. 
Dot blot analysis for polyA mRNA was performed on total RNA isolated from 
approximately 50 mg of snap frozen liver tissue using the RNeasy kit following standard 
protocols. 250 ng of total RNA was blotted onto membrane as described previously for 
DNA-RNA hybrid assay. Membrane was UV crosslinked and air dried before continuing. 
The blot was prehybridized with ULTRAhyb-Oligo Hybridization Buffer (Thermo Fisher 
Scientific) for 10 minutes at 42 °C with gentle agitation in a hybridization oven. PolyA 
mRNA was detected using biotinylated oligo-dT probes (Promega #Z5261). Probe was 
diluted in ULTRAhyb-Oligo Hybridization Buffer (0.5 µL of 5 pmol/uL per mL of buffer). 
Blot was incubated with probe solution at 42 °C for 1 hour. Blot was then washed twice 
with ULTRAhyb-Oligo Hybridization Buffer. Chemiluminescent detection was performed 
using the Chemiluminescent Nucleic Acid Detection Module Kit (Thermo Fisher Scientific 




5.3.1 RNA-seq Analysis of acSRSF1 HKO Reveal Transcriptome-wide Defects 
Like SRSF1 HKO, RNA-seq was performed in acSRSF1 HKO model at the 2-week 
timepoint. This timepoint was chosen as the severe pathological changes have not yet 
developed. Differential gene expression and splicing analysis reveal a substantial number 
of changes to the transcriptome. With regards to expression, over 3,700 genes were 
found to be differentially expressed (Figure 5.1 A). This corresponds to nearly 30% of the 
hepatocyte transcriptome. Furthermore, a greater proportion of genes are upregulated 
with 2,525 genes which accounts for nearly two-thirds of all DEGs. 
In addition to gene expression changes, acSRSF1 HKO showed significant 
changes in differential splicing (Figure 5.1 B). A total of 2,996 splicing events were found 
to be significantly changing in PSI between control and acSRSF1 HKO. Like SRSF1 HKO, 
the event type with the largest representation was SE with a total of 2040 events. 
Furthermore, a larger proportion of events exhibited decreases inclusion with loss of 
SRSF1. For instance, about 70% of the differentially spliced SE events were found to 
have decreased inclusion. 
It is known that differential splicing can affect the stability of transcripts which can 
shift steady state abundances of transcripts. To determine if splicing and gene expression 
are dependent, an overlap between the two sets was performed (Figure 5.2). A total of 
248 genes were found to be differentially spliced and expressed in acSRSF1 HKO. The 
calculated p-value for the overlap was 0.30 and therefore was not found to be significant. 
Furthermore, of the overlapped genes, about 54% of the genes exhibited downregulation. 
Therefore, it appears the differential splicing and gene expression are independent.  
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5.3.2 Splicing Defects in acSRSF1 HKO are Indirect Effects of SRSF1 Loss 
Differential splicing analysis in the acSRSF1 HKO revealed widespread defects in 
exon usage. However, to determine which of the differentially spliced exons are directly 
regulated by SRSF1, an eCLIP-seq experiment was performed in hepatocytes isolated 
from wildtype mice. This analysis revealed a total of 5,727 significant unique peaks for 
SRSF1 in hepatocytes (Figure 5.3 A). Most binding of SRSF1 is found within exons, 
followed by introns and then exon-intron boundary. To determine the type of genes on 
which SRSF1 binds, a gene ontology was performed on all the genes with SRSF1 binding 
(Figure 5.3 B). The analysis shows enrichment for genes involved in RNA binding and 
metabolic processes such as lipoprotein particle receptor binding and sterol transport. 
To further investigate the direct effects of SRSF1 ablation on the transcriptome, 
the identified peaks was overlapped with the genes changing in expression or splicing 
(Figure 5.4). Surprisingly, of all the identified SRSF1 binding peaks, about 7% were found 
to have binding on exons with differential splicing in the acSRSF1 HKO. This is lesser 
than the overlap with genes found to be downregulated in expression with 17.4% of 
binding peaks. This suggests that the widespread splicing defects observed in acSRSF1 
HKO is independent of direct SRSF1 binding. It has been seen that RNA binding proteins 
can have preferential binding to certain regions of mRNA, such as the CDS, 5’ UTR, and 
3’ UTR. Binding in particular regions can confer different regulatory effects such as 
stability or transportation. Determination of SRSF1 binding propensity regarding region 
type shows that SRSF1 binds primarily to CDS. This suggests that SRSF1 does not have 
varying propensity by type since CDS make up a larger portion of mRNA. Furthermore, 
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the proportion of SRSF1 binding by mRNA region does not change drastically for genes 
that are changing in expression or splicing (Figure 5.5).  
Analysis of the spatial distribution of SRSF1 binding was performed on the 
differentially skipped exon set from acSRSF1 HKO (Figure 5.6). Since it is likely that the 
differentially skipped exons in the acSRSF1 HKO are regulated by SRSF1, it is expected 
that these events would exhibit enrichment of SRSF1 binding peaks. Shockingly, 
compared to a background constitutive exon set, there is a striking de-enrichment of 
SRSF1 binding in the differentially spliced exons. This provides further support that the 
splicing defects detected in acSRSF1 HKO is independent of SRSF1 known splicing 
activity. Motif analysis was also performed on the identified SRFS1 binding peaks (Figure 
5.7 A). The peaks enriched for the canonical GAAGAA motif that has been found in 
previous SRSF1 binding studies. The spatial distribution of this motif was found to be 
enriched within exonic regions (Figure 5.7 B). A second motif with the sequence 
CUA/UCA was also found to be enriched in the SRSF1 binding peaks. However, strong 
spatial enrichment of this motif within exon regions was not found. Instead enrichment 
was found in intronic regions, however, the functionality of this motif is not clear. 
An interesting observation noticed of the genes with SRSF1 binding is that the 
distribution of expression changes reveals there to be an overall decrease in abundance 
in acSRSF1 HKO model (Figure 5.8). A possible explanation of this finding is that binding 
of SRSF1 to these genes confers additional stability. Therefore, loss of SRSF1 leads to 
destabilization of the mRNA resulting in decreased steady state levels of the transcript. 
This is possible because it is known that SRSF1 is involved in forming EJC complex which 
facilitates compaction of mRNA and provides stability. 
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5.3.3 Gene Ontology Analysis Reveals DNA Damage Response in acSRSF1 HKO 
To investigate the gene regulatory networks affected in acSRSF1 HKO, gene 
ontology analysis was performed on the differential gene expression and splicing data. 
The resulting gene ontology network revealed enrichment of multiple biological processes 
(Figure 5.9).  Like SRSF1 HKO, acSRSF1 HKO displayed a strong upregulated 
enrichment for processes involved in immune response. This suggests that even at this 
early timepoint, loss of SRSF1 triggers the hepatocytes to activate signals for recruitment 
of inflammatory cells. It is possible that these signals are further exacerbated by the 
introduction of viral vectors into the liver. A strong enrichment is also observed for 
regeneration response. At this timepoint, the hepatocyte functions are beginning to 
decrease which is likely triggering an early compensatory response to begin repopulating 
the tissue with additional hepatocytes. Interestingly, the network map also shows a strong 
upregulation for processes involved in DNA repair and cell cycle in the setting of acSRSF1 
HKO. These terms also have a strong overlap with genes that were also found to have 
differentially spliced exons. It is known that SRSF1 is plays a role in maintaining genome 
stability. Therefore, loss of SRSF1 is resulting in DNA damage which is triggering a DNA 
damage repair response. 
5.3.4 AcSRSF1 HKO do not Exhibit Activation of the Unfolded Protein Response 
A possible mechanism of the pathological findings observed in the SRSF1 HKO 
models is that loss of SRSF1 is resulting in accumulation of unfolded proteins. 
Specifically, absence of SRSF1 is leading to transcription of transcripts deficient of 
constitutive exons which will eventually be translated into aberrant proteins. These 
aberrant proteins will then lead to accumulation of improper folding and activation of the 
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unfolded protein response. To investigate this hypothesis, heatmaps for UPR responsive 
genes were generated (Figure 5.10 A). It is evident from the heatmaps that there is a 
strong downregulation of UPR genes. Furthermore, a canonical response to the UPR is 
the splicing of the Xbp1 gene. Presence of unfolded proteins within the ER lumen results 
dimerization of IRE1 and subsequent unconventional splicing of Xbp1 leading to the 
formation of a short isoform (Dara, Ji, and Kaplowitz 2011). The splicing of this exon is 
unchanged in acSRSF1 HKO mice (Figure 5.10 B). Finally, UPR also leads to increased 
levels of CHOP, a UPR downstream effector protein and transcription factor (Samali et 
al. 2010; Oslowski and Urano 2011). The levels of this protein are also unchanged in 
acSRSF1 HKO hepatocytes (Figure 5.10 C). Taken together, it is highly unlikely that loss 
of SRSF1 is resulting in accumulation of unfolded proteins leading to proteotoxic affects. 
5.3.5 DNA Damage in SRSF1 HKO is Likely Mediated by R-Loop Accumulation 
Gene ontology analysis revealed that loss of SRSF1 triggers a DNA damage repair 
response. It is well established that SRSF1 is involved in maintaining genome integrity. 
This is due to SRSF1’s ability to reduce the formation of R-loops which are DNA-RNA 
hybrid structures. Loss of SRSF1 is known to cause accumulation of these structures as 
genes are being transcribed. This overwhelming formation of R-loops leads to DNA 
double strand breaks as the cell is not able to resolve them. To determine if DNA damage 
is present in the acSRSF1 HKO mice, immunofluorescent staining for γH2A.X, a well-
known marker of DNA damage, was performed on tissue from acSRSF1 HKO (Mah, El-
Osta, and Karagiannis 2010). In agreement with this hypothesis, robust signal for γH2A.X 
is seen in the acSRSF1 HKO mice (Figure 5.11). Furthermore, this signal is also 
observed in SRSF1 HKO at the 10-day and 1-month timepoint. Next, to confirm that this 
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DNA damage is likely a result of increased accumulation of R-loops. A S9.6 dot blot assay 
was performed using DNA isolated from acSRSF1 HKO. The S9.6 antibody specifically 
binds to DNA-RNA hybrids. The dot blot shows robust signal in SRSF1 knockout samples 
for DNA-RNA hybrids in both the acSRSF1 HKO and SRSF1 HKO models (Figure 5.13 
A). It has been shown that the widespread accumulation of R-loops results in blockage 
of transcription. It can be expected that blockage of transcription will result in decrease 
production of nascent mRNA and therefore a decrease in steady state abundance of 
polyA mRNA.  
To determine if inhibition of global transcription may be occurring in SRSF1 
knockout hepatocytes, a dot blot using a polydT probe was performed on total RNA to 
determine steady state levels of polyA mRNA (Figure 5.13 B). Indeed, a significant 
decrease in total polyA mRNA is observed in SRSF1 HKO samples compared to controls. 
It should be noted that equivalent amounts of total RNA were blotted in this assay. 
Therefore, this assay does not provide information regarding absolute quantities of polyA 
mRNA. The levels of polyA mRNA relative to total RNA is decreased in SRSF1 HKO 
hepatocytes. Since mRNA makes up about 3% - 5% of total RNA, this assay provides 
insight into the differences in abundance of polyA mRNA relative to the total RNA pool. 
While it is expected that relative abundance of polyA mRNA relative to the total RNA pool 
will decrease in the setting of decreased global transcription, this observation would be 
expected in multiple cases. For instance, increased degradation of polyA mRNA would 





Extensive characterization of SRSF1 HKO mice demonstrated that loss of SRSF1 
activity in hepatocytes results in cellular death. This is not unexpected since previous 
reports have shown that knocking out SRSF1 is embryonically lethal. However, to 
determine the molecular mechanisms leading the demise of the cell was not clear. 
Significant effort was placed in understanding the transcriptome changes occurring in the 
model using techniques such as RNA-seq and eCLIP-seq. However, these efforts did not 
provide the great insight. Analysis of the RNA-seq and SRSF1 binding data showed that 
most of the observed transcriptome changes were not a result of SRSF1’s splicing 
deficiency (Figure 5.5 and 5.7). The motivation for utilizing these methodologies was 
based on the hypothesis that loss of SRSF1 was leading to misregulation of a specific set 
of transcripts needed for the viability of the cell. In retrospect, this hypothesis was 
completely incorrect. Fortunately, analysis of the acSRSF1 transcriptome shed light into 
the possibility of DNA damage response and repair (Figure 5.10).  
Further investigating this possibility showed that DNA damage was occurring in 
the SRSF1 HKO models (Figure 5.12). In fact, multiple reports have shown that loss of 
SRSF1 activity results in genome instability. It was shown that deficiency of SRSF1 
causes a robust accumulation of R-loops which are three-stranded nucleic acid structures 
composed of DNA-RNA hybrids (X. Li and Manley 2005; X. Li, Niu, and Manley 2007). 
Formation of these structures occurs at some basal frequency in all cells during 
transcription, however, a healthy cell can resolve them without leading to DNA damage. 
But, conditions in which the frequency of R-loop formation increases, the cell can be 
overwhelmed and fails to resolve these structures leading to DNA double strand breaks. 
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In addition to all the activities of SRSF1, it is also involved in preventing the formation of 
R-loops. This is presumably due to the co-transcriptional binding of mRNA preventing it 
from annealing back to the template DNA (Tous and Aguilera 2007).  
Revelation of this understanding completely changed the hypothesis regarding the 
molecular mechanism resulting in death of SRSF1-deficient hepatocytes. It is well 
established, that the DNA damage resulting from SRSF1 knockout is most likely due to 
R-loop formation. To confirm if SRSF1 knockout model also show accumulation of R-
loops, a dot blot assay using the S9.6 antibody was used which detects DNA-RNA 
hybrids. Indeed, this assay showed a striking signal for R-loop presence in DNA isolated 
from the SRSF1 knockout mice (Figure 5.13 A). Therefore, the demise of the SRSF1-
deficient hepatocytes is most likely due to the extensive and unresolvable DNA damage 
induced by R-loop accumulation. With the widespread accumulation of R-loops in SRSF1 
HKO, it is expected that global transcription will be blocked. To shed some light into this 
possibility, relative polyA mRNA levels were quantified by a dot blot northern assay using 
a polydT probe (Figure 5.13 B). Results from this assay revealed a significant decrease 
in relative steady state levels of polyA mRNA in SRSF1 HKO. 
It should be noted that this assay measures the steady state levels of polyA mRNA 
and not nascently transcribed mRNA. The hypothesis is that loss of SRSF1 is resulting in 
a decrease of global transcription leading to subsequent decrease of total RNA. Since 
non polyadenylated ribosomal RNA makes up about 80% of total RNA, the decreased 
signal for polyA mRNA signifies that relative abundance of polyA mRNA to total mRNA is 
decreasing. If loss of SRSF1 is indeed resulting in decreased transcription globally, the 
decreased polyA signal seen in this assay suggests that the polyA mRNA exhibit higher 
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turnover rates in comparison to ribosomal RNA. This higher turnover rate will result in 
greater difference in relative polyA mRNA abundance to total RNA which would allow for 
differences in the polyA mRNA signal to be detected. However, this result would also be 
seen in the case if SRSF1 knockout was inducing higher turnover rates of polyA mRNA. 
To truly prove that global mRNA transcription is decreased in SRSF1 HKO, another 
technique must be utilized such as metabolic labeling of nascent mRNA. 
Finally, it should be stated that the transcriptome data did provide strong evidence 
that the pathological effects of SRSF1 deficiency is not a result of toxic protein 
accumulation. A possible hypothesis of toxic effects of SRSF1 deficiency is due to the 
generation of mispliced transcripts which translate into aberrant proteins that do not fold 
properly. This would result in the activation of the Unfolded Protein Response or UPR. 
Multiple pieces of evidence in the SRSF1 HKO model reject this mechanism. This 
includes gene expression data which shows downregulation of UPR genes, no induction 
of CHOP levels by western blot analysis and no change in XBP1 splicing (Figure 5.11). 
This is understandable since the loss of SRSF1 is leading to damage at the transcription 




5.5 Chapter Figures 
 
 Gene Expression and Exon Splicing Distributions in acSRSF1 HKO 
(A) Volcano plot showing changes in mRNA abundances from RNA-seq (n = 3 samples per 
condition) in hepatocytes from acSRSF1 HKO 2 weeks post viral induction. A total of 3717 
genes are changing in gene expression with over two-thirds being upregulated. (B) 
Histogram showing distribution of calculated ΔPSI from RNA-seq for each splicing event 
type. The dotted line marks the median of the distribution. A larger percentage of exons 







 Overlap Between Gene Expression and Splicing in acSRSF1 HKO 
Venn diagram showing breakdown of the number of genes with differential gene 
expression and splicing and the overlap between the two sets. The red values signify the 
number of events. The overlap between the two sets are not significant (p value > 0.05), 









 SRSF1 eCLIP Peak Summary and Gene Ontology Analysis 
SRSF1 eCLIP-seq was performed using hepatocytes isolated from C57BL/6j mice. Peaks 
were then identified using Clipper and then annotated using custom python scripts. (A) A 
graph showing the number of SRSF1 binding peaks found at the indicated pre-mRNA 
region. (B) Gene Ontology analysis of all genes with SRSF1 binding peaks. Genes with 






 Overlap of SRSF1 Binding Peaks with SRSF1 Regulated Genes 
Venn diagram showing the breakdown of SRSF1 binding peaks overlapping with genes 
changing in expression or splicing in the acSRSF1 HKO model. A large percentage (~70%) 
of SRSF1 binding peaks are localized on genes which were not found to be changing in 
expression or splicing in the acSRSF1 HKO. The second largest fraction (~17%) of SRSF1 
binding peaks were associated with genes found to be downregulated. This is followed by 
peaks associated with differential splicing and then upregulated genes (5.8% and 5.1%, 
respectively). This pattern also holds for the inverse relationship. Of the SRSF1 regulated 
gene sets, genes downregulated in acSRSF1 HKO had the highest percentage of genes 
with SRSF1 binding. This was followed by genes with differential splicing and then 




 Breakdown of SRSF1 Binding Peaks by Localization on mRNA Regions 
The three main regions of a transcript include 5’ UTR, CDS, and 3’ UTR. Of the three 
regions, the CDS often takes the largest portion of a transcript. To understand if SRSF1 
preferentially bound one region over the other, a breakdown of the SRSF1 binding peaks 
by the associated mRNA region was determined. This analysis was then further performed 
on the sets of peaks bound to genes that were regulated in acSRSF1 HKO. As expected, 
for all peaks SRSF1 was found to bind to primarily the CDS region. The ratio of binding 
peaks by region do not drastically shift based on association with regulated genes. 
Although peaks on genes with differential splicing did show significantly higher portion 






 Spatial distribution of SRSF1 Binding Peaks on Differentially Spliced 
Cassette Exons in acSRSF1 HKO 
Cumulative peak density plot of SRSF1 binding peaks on the 2,040 differentially spliced 
cassette exons (green line) in acSRSF1 HKO model. A set of 23,905 constitutive exons 
were used as background. The background set was sampled 1,000 to determine the 95% 
confidence interval of peak density at each nucleotide position. The background set shows 
strong enrichment at exon boundaries. It is apparent that the differentially spliced exons 
show a strong decreased peak density compared to the background. Furthermore, a native 
cassette exon set was also used for comparison which consists of exons found to be 
alternative (0.05 < ΔPSI < 0.95) but did not change significantly upon SRSF1 knockout. 







 Motif Analysis of SRSF1 Binding Peaks in Hepatocyte eCLIP-seq Dataset 
(A) Motif enrichment analysis was performed on SRSF1 binding peak regions using MEME 
suite. Two highly enriched motifs are presented for each set type. For all SRSF1 peaks the 
canonical GAAGAA motif was enriched. This was the case for binding peaks associated 
to regulated gene sets. The second motif enriched in the downregulated gene set included 
a CUAUCA motif. (B) Cumulative spatial distribution of the enriched motifs relative to exon 
coordinates. Enrichment of the GAAGAA motif was found within exon region. The 





 Genes with SRSF1 Binding Exhibit Decreased Abundance in acSRSF1 HKO 
Box plots showing distribution of Log2 fold change values for genes with and without 
SRSF1 binding. A total of 982 genes showed SRSF1 binding from eCLIP-seq. Genes with 
SRSF1 binding exhibited decreased transcript abundances in acSRSF1 HKO in 
comparison to genes which showed no binding. A possible explanation for this 
observation is that SRSF1 provides additional stability to transcripts. However, with 
absence of SRSF1 in the knockout model, these set of mRNA are destabilized and have 







 Gene Ontology Network Map of Genes with Differential Expression and 
Splicing in acSRSF1 HKO Model 
A gene ontology network map representing the gene ontology terms enriched in the 
combined set of upregulated, downregulated, and differentially spliced genes. The size of 
the node provided the number of genes associated with the node. The node color 
represents the fraction of genes in the node either upregulated or downregulated. Finally, 
nodes with blue outline represent nodes that contain genes that are differentially spliced. 
A significant fraction of nodes show that upregulated genes enrich for terms involved in 
immune response and regeneration. Furthermore, an enrichment for terms involved in 






 Acute SRSF1 HKO do not Exhibit an Unfolded Protein Response 
(A) Heatmap showing expression of genes involved in the UPR response in acSRSF1 HKO 
model. Many genes are downregulated with no evidence of induction of expression. (B) 
Splice gel of the canonical XBP1 splicing event responsive to UPR. No change in splicing 
is observed in acSRSF1 HKO. (C) Western blot analysis for CHOP expression in acSRSF1 






 Loss of SRSF1 Activity Results in Immediate DNA Damage 
IF imaging of the DNA damage marker, γH2A.x, on acSRSF1 HKO and SRSF1 HKO liver 
tissue sections at the indicated timepoints. Images show representative hepatocyte nuclei 
among multiple samples per group (n = 4-5 per group). Loss of SRSF1 results in robust 




 Loss of SRSF1 Leads to Accumulation of R-Loops 
(A) Representative blots of RNA-DNA hybrid dot blot assays using the S9,6 antibody on 
purified DNA from control and knockout samples from 2-week acSRSF1 HKO and 10-day 
SRSF1 HKO (n = 4 per group). Corresponding dot blot for dsDNA was performed as loading 
control. Presence of R-loop is confirmed with RNAse H treatment which results in the 
cleavage of R-loops and loss of signal. Striking signal is seen in knockout samples 
confirming accumulation of R-loops. (B) PolyA mRNA on 500 ng of isolated total RNA using 
a polydT probe. Total RNA gel electrophoresis image is shown for confirmation of equal 




 SRSF1 Knockout Leads to Global Translation 
Defect and Necroptosis 
 
6.1 Introduction 
It is now evident that loss of SRSF1 activity in hepatocytes results in widespread 
accumulation of R-loops and subsequent DNA damage. This activity of SRSF1 is a vital 
function in general physiology and is essential in protecting the genome from R-loop 
induced DNA damage. However, it is still not yet clear what are the downstream effects 
and responses to the widespread DNA damage. To gain further insight into the 
downstream effects, a global proteomics study was performed on hepatocytes isolated 
from acSRSF1 HKO. Understanding the changes occurring to the hepatocyte proteome 
will provide an overall picture of the mechanisms resulting in the eventual cell death. 
With regards to understanding the eventual demise of the hepatocyte, previous 
investigations suggest the cells do not undergo apoptosis. This is apparent from the 
negative TUNEL staining. Histological appearance of the cell suggests the hepatocytes 
may likely be undergoing necrosis. To further investigate this possibility, western blot 




6.2 Material and Methods 
6.2.1 Global Proteomics Analysis of Hepatics Proteins by Mass Spectrometry 
Samples were processed for proteomics according to the FASP protocol and 
desalted on an in-house prepared C18 tips (Wiśniewski et al. 2009). The peptides were 
separated on an EASY Spray C18 column (50 cm x 75 cm, 2 µm particle size) 
(ThermoFisher Scientific, Toronto) using an EASY nLC-1200. The mobile phase was 
composed of 0.1% formic acid in water (A) and 90% acetonitrile with 0.1% formic acid 
(B). The gradient was as follows: 5 - 40% B (0 – 120 minutes), 40% - 100% B (120 – 125 
minutes), 100% B (125 – 135 minutes). The peptides were analyzed on a Thermo Q 
Exactive HF mass spectrometer in a Top 20 data dependent acquisition mode. Proteins 
were identified by searching the mouse (UP000000589) proteomes from UniProtKB 
(February 2019). Peptide spectral matches, and protein False Discovery Rates were set 
to 1%, and requiring a minimum of 1 unique peptide for identification. To increase the 
number of identified matches, match between runs” was enabled with a match time 
window of 0.7 minutes. Protein abundances were calculated using the iBAQ algorithm in 
MaxQuant. 
6.2.2 Polysome Profiling of Isolated Hepatocytes from Acute SRSF1 HKO Mice 
Polysome profiling was performed on acSRSF1 HKO mice at 2 weeks post 
injections of viral vectors. Isolated hepatocyte samples were prepared for both control 
(AAV8-TBG-GFP) and acSRSF1 HKO (AAV8-TBG-Cre) for polysome profiling following 
a previously described protocol (Seimetz et al. 2019). Hepatocytes were isolated in the 
same manner as described in Section 9.1.2 with every buffer supplemented with 150 
µg/mL cycloheximide. The pellets were flash frozen in liquid nitrogen and stored at -80 
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°C until ready for polysome fractionation. Frozen hepatocytes were thawed on ice for 15 
minutes with 1 mL of polysome lysis buffer containing 10 mM Tris-HCl (pH 8.0), 150 mM 
NaCl, 5 mM MgCl2, 1% Nonidet-P40, 40 mM dithiothreitol, 1 U/mL SUPERaseIn RNase 
inhibitor (Thermo Fisher) and 150 µg/mL cycloheximide. Thawed cells were pipetted 
gently 10 times to ensure lysis of cytoplasm. The cell nuclei and debris were removed by 
centrifugation at 12,000 x g for 1 minute at 4 °C. The supernatant was transferred to a 
fresh tube and then centrifuged again at 16,000 x g for 7.5 minutes at 4 °C to remove 
remaining cell debris and organelles. The resulting supernatant was transferred to a fresh 
tube and about 400 µL supernatant was layered onto a 12 mL linear sucrose gradient (10 
– 50% sucrose (w/v) made using a Biocomp Gradient Master) and centrifuged in an SW-
41Ti rotor (Beckman) for 125 minutes at 38,000 r.p.m. at 4 °C. The fractionated sample 
was gently moved through the detector using a peristaltic pump set at 3.5 mL/min with 
60% sucrose as the chase solution. Polysome profiles were measured with a UA-6 
absorbance (ISCO) detector at 254 nm and recorded using the associated Peak Chart 
software. 
6.2.3 Global Translation Quantification using the SUnSET assay 
Translating proteins were labeled using a protocol adapted from the Surface 
Sensing of Sensing of Translation (SUnSET) method (Goodman and Hornberger 2013; 
Goodman et al. 2010). The assay was performed on Control and acSRSF1 HKO mice at 
2 weeks post injections of viral vector. Mice were injected with puromycin prepared in 
sterile PBS (0.04 µmol/gram body weight). After 45 minutes, livers were harvested, and 
protein lysates were prepared as described in Section 9.1.3. Proteins were separated by 
10% SDS-PAGE. Puromycin-labeled peptides were identified using the mouse 
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monoclonal antibody 12D10 (EMD Millipore Catalog# MABE343). Protein synthesis 
levels were determined by densitometry analysis of whole lanes. 
6.2.4 Serum Fractionation for Lipoprotein Particle Analysis 
Plasma was collected from both control and acSRSF1 HKO mice at 2 and 4 weeks 
post viral injection as described in Section 2.2.2 after a 6 hour fast starting from noon to 
6 p.m. Plasma (~ 200 µL) was injected onto a Superose HR6 10/300 GL FPLC column 
(GE Healthcare). Lipoproteins were eluted with 24 mL of elution buffer containing 0.15 M 
NaCl, 1 mM EDTA, 0.2% w/v of sodium azide in PBS and 0.5 mL fractions were collected 
at a flow rate of 0.5 mL/min. Triglyceride and cholesterol concentration was measured 
using Infinity kits (Thermo Scientific). In a microtiter plate, 100 µL of plasma as well as 
standards were incubated with 100 µL of Infinity reagent and then incubated at 37 °C for 
30 minutes. The plates were measured for absorbance using a BioTek machine at 500 






6.3.1 Global Mass Spectrometry Analysis Reveals Depletion of Ribosomal Proteins 
Global protein abundance estimates by mass spectrometry was able to detect a 
total of 3,603 proteins. Performing differential abundance analysis between control and 
acSRSF1 HKO hepatocytes reveals numerous proteins changing in abundances. 
Specifically, 613 different proteins were detected to be decreasing in abundance while 
159 were found increasing (Figure 6.1). It is not surprising that a greater proportion of 
proteins are decreasing in abundance since to cells is most likely shutting down 
translation in response to DNA damage. 
Intersection of the proteomics data was performed with the available transcriptome 
data obtained for the acSRSF1 HKO model. Specifically, intersection was performed with 
corresponding genes with SRSF1 binding, gene expression changes, and splicing 
changes (Figure 6.2 A-D). The intersection revealed expected findings such as genes 
found to be downregulated or upregulated in mRNA abundance also showed abundance 
changes in the same direction. No significant effects on abundance was found for genes 
exhibiting SRSF1 binding or differential splicing events. 
One of the early concerns regarding the SRSF1 HKO model was the possibility of 
induction of other SR proteins to compensate the deficiency of SRSF1. This was not 
feasible as it would require obtaining the antibodies for the other 11 members of the SR 
family. However, this question can easily be answered by the estimations provided by the 
proteomics data. Estimations of the other SR protein factors show that except for SRSF4, 
all other SR protein abundances are stable and do not change between control and 
SRSF1 knockout (Figure 6.3). SRSF1 was of course found to be significantly 
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downregulated as expected and SRSF4 was slightly increased in abundance. 
Interestingly, SRSF3, which has been shown to be involved in hepatocyte differentiation, 
has the highest abundance of all the SR proteins (Sen, Jumaa, and Webster 2013). 
To gain an unbiased view of the various processes the differentially abundant 
proteins are involved with, a gene ontology analysis was performed. Results from the 
analysis show that the downregulated proteins are strongly enriched for ribosomal 
proteins and factors involved in translation (Figure 6.4). Proteins that are increasing in 
abundance are enriched for factors involved in lipoprotein and cholesterol metabolism. 
To further understand the extent of downregulation of ribosomal proteins in acSRSF1 
HKO, a heatmap was generated depicting the abundance changes of all detected 
proteins involved in translation (Figure 6.5). Surprisingly, a striking and pervasive 
downregulation of ribosomal proteins, translation initiation factors, and tRNA synthetases 
is found at the level of protein abundance. However, mitochondrial ribosomal proteins 
showed an increase. 
The remarkable downregulation of ribosomal proteins seen from the proteomics 
data suggests that acSRSF1 HKO mice will exhibit impaired translation. It is also known 
that Non-sense mediated decay (NMD) is dependent on translation. Therefore, 
impairment in translation activity will result in impairment of NMD. Impaired NMD would 
lead to increased abundance of intron containing NMD transcripts. To investigate this 
possibility, a global intron retention analysis was performed on the acSRSF1 HKO RNA-
seq data (Figure 6.6). Indeed, results from the intron retention analysis show that there 
is a robust increase in the levels of intron containing transcripts. This widespread 
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detection of intron containing transcripts further supports the notion that NMD is impaired 
rather than misregulation of SRSF1 mediated splicing of these transcripts. 
6.3.2 Polysome Profiling of acSRSF1 HKO Hepatocytes Shows Absence of Polysomes  
Proteomics and transcriptomics data from acSRSF1 HKO mice suggest there may 
be a defect in translation upon loss of SRSF1. To test this hypothesis, polysome profiling 
was performed since it can allow for the determination of ribosomal occupancy changes 
between two conditions. One possibility is that certain transcripts may exhibit lower 
translation upon knock-out of SRSF1. It is known that SRSF1 can regulate the translation 
of target mRNAs. Since polysome profiling results in the separation of mRNAs based on 
its ribosomal occupancy, differences in occupancy can be measured between Control 
and acSRSF1 HKO. Separation is performed on a sucrose gradient and mRNAs with 
increasing ribosomal occupancy appear as peaks on the chromatogram.  
Surprisingly, the polysome profiles of acSRSF1 HKO show a near complete loss 
of polysomes (Figure 6.7). While a monosome peak is present in the acSRSF1 HKO, 
subsequent peaks corresponding to polysomes are not which can be seen in Controls. 
This result agrees with the previous proteomics and transcriptomics data. Loss of higher 
polysomes suggests loss of SRSF1 results in a severe defect in translation. Interestingly, 
the profile for acSRSF1 HKO show the presence of a monosome peak. It is not clear if 
these are functional ribosomes translating the corresponding mRNA or if these are stalled 
ribosomes on the mRNA. To answer this question a different approach is required. While 
there is a correlation between ribosomal occupancy and translation rates, this technique 




6.3.3 Global Translation is Diminished in acSRSF1 HKO Hepatocytes 
Polysome profiling revealed absence of polysomes in acSRSF1 HKO. While this 
would suggest that global translation is impaired in acSRSF1 HKO, it does not provide 
definitive proof. To investigate the rate of global protein synthesis in the acSRSF1 HKO 
model, a SUnSET assay was performed. This assay is a pulse-chase experiment based 
on incorporation of puromycin to nascently synthesized proteins. Proteins are then 
isolated from the tissue and then western blot analysis is performed using puromycin 
antibody. The resulting signal is normalized to total protein signals to determine the rate 
of global protein synthesis. The assay was performed on acSRSF1 HKO mice at the 2-
week timepoint (Figure 6.8 A). In addition to the liver, spleen was collected as a normal 
tissue control from the acSRSF1 HKO model. Quantification of the puromycin 
incorporation shows that acSRSF1 HKO have severely diminished protein synthesis 
activity (Figure 6.8 B). This provides strong proof that global translation in acSRSF1 HKO 
mice is diminished. 
6.3.4 Lipoprotein Particle Formation is Depleted in SRSF1 HKO Mice 
Due to the dramatic decrease in global protein synthesis in acSRSF1 HKO 
hepatocytes, these hepatocytes are expected to display deficiency in their overall 
functions. One of the major functions of a hepatocyte is the processing of lipids into 
lipoprotein particles and release into circulation for systemic delivery. Hepatocytes 
generate most high-density lipoprotein particles that are present in circulation. To 
determine if acSRSF1 HKO have impairment in lipoprotein particle formation, 
fractionation was performed on serum collected from fasted mice at the 2- and 4-week 
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timepoint (Figure 6.9). As expected, serum at the 4-week timepoint are depleted of HDL 
particles suggesting that liver is failing to synthesize the particles. 
6.3.5 Western blot Analysis of p53, eIF2α, and Cell Death Factors 
It is evident that SRSF1 knockout results in striking impairment of global 
translation. However, the mechanism resulting in the global shutdown of translation is not 
yet clear. One possible explanation is that the widespread DNA damage is activating p53 
which is known to subsequently result in the global shutdown of translation. This response 
is thought to protect the cell from generating aberrant protein and to focus efforts into 
repairing the damaged DNA. To this investigate this hypothesis, western blot analysis 
was performed for total p53 and phospho-p53 (S15) which is the active form (Figure 
6.10). Surprisingly, p53 activation is not seen by western blot analysis in acSRSF1 HKO 
timepoints. It is also known that phosphorylation of eIF2α signals shutdown of global 
translation. It is possible that DNA damage could lead to global translation inhibition via 
phosphorylation of eIF2α. However, like p53, eIF2α was not found to be deactivated in 
acSRSF1 HKO (Figure 6.10). 
Western blot analysis was also performed to measure BAX and RIPK1 proteins, 
which are classical apoptosis and necrosis factors, respectively. Interestingly, both BAX 
and RIPK1 showed robust induction at the 4-week timepoint in acSRSF1 HKO model 
(Figure 6.10). This suggests that the cell death occurring in this model is via necroptosis, 
explaining why the TUNEL staining are negative. Due to the impairment of global 
translation it is likely that the SRSF1-deficient cell is not able to trigger the apoptosis 




Global proteomics data showed a striking downregulation of multiple factors 
involved in the initiation of translation and ribosomal proteins (Figure 6.5). It was 
hypothesized that diminished levels of these factors would lead to impairment of global 
translation. To test this hypothesis, both polysome profiling and SUnSET assays were 
performed on acSRSF1 HKO hepatocytes at the two-week timepoint. Polysome profiling 
allows for the isolation and separation of mRNAs based on the number of bound 
ribosomes. Transcripts which are translated at a higher efficiency tend to have a greater 
number of bound ribosomes. Indeed, results from this assay showed that acSRSF1 mice 
had an absence of polysomes (Figure 6.7). While this assay provides insight of the 
polysome distribution in the cell, it does not give direct estimate of translation rates or 
protein synthesis.  
To address this question, the SUnSET assay, a nonradioactive method to monitor 
protein synthesis, was utilized. This technique employs the use of the antibiotic 
puromycin, a structural homolog of tyrosyl-tRNA, which can be readily incorporated into 
nascent peptide chains. Using an anti-puromycin antibody, the amount of puromycin 
incorporation can be quantified with western blotting, hence, providing an indirect 
measure of protein synthesis. In agreement with the proteomics and polysome profiling 
data, acSRSF1 HKO exhibited severely diminished rates of global protein synthesis 
(Figure 6.8). Taken together, loss of SRSF1 activity results in eventual cessation of global 
translation. However, it is unclear what triggers this shutdown of translation. 
To further investigate possible mechanism of translation shutdown, western blot 
analysis was utilized to probe levels of known factors involved in translation inhibition. A 
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possible mechanism resulting in translation inhibition is activation of p53 since DNA 
damage is present in acSRSF1 HKO. It is known that activated p53 triggers shutdown of 
global translation. Surprisingly, p53 was not activated in the by western blot analysis. 
There is now upcoming evidence showing that there are conditions in which DNA damage 
results in a p53-indpendnet response (Fagan-Solis et al. 2020; Riepe et al. 2018). Another 
possible explanation of the absence of p53 activation is that the activation occurs within 
a short window which was not captured at the timepoints which were collected. A second 
possible mechanism of global translation inhibition is phosphorylation of eIF2α. This event 
is a well-established mechanism for cause global translation inhibition. Like p53, 
phosphorylation of eIF2α was also absent in the acSRSF1 HKO. Currently, the 
mechanism resulting in the inhibition of translation is not clear and further investigation is 
required. 
Western blot analysis was also performed for BAX and RIPK1 which are known 
apoptosis and necrosis factors, respectively. Interestingly, both factors were in the 
acSRFS1 HKO, indicating that the SRSF1-deficient hepatocytes undergo necroptosis 
(Figure 6.10). This explains the negative TUNEL staining in the SRSF1 HKO mice. Due 
to the global impairment of translation, it is possible that factors necessary for the 
complete execution of apoptosis may be deficient. Therefore, the failed apoptosis might 
result in eventual necrosis as seen by the elevated levels of RIPK1.  
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6.5 Chapter Figures 
 
 AcSRSF1 HKO Hepatocytes Exhibit Extensive Remodeling of the Proteome 
Volcano plot depicting the changes in protein abundances estimated from global proteome 
analysis on hepatocytes isolated from control and acSRSF1 HKO mice using mass 
spectrometry (n = 3 per group). A total of 3,603 proteins were detected from mass 
spectrometry. Of the 772 proteins identified to be significantly changing in abundance 
(Log2 Fold Change > 1 and FDR < 0.1), 613 (~79%) were found to be downregulated. 
Differential abundance was determined by calculating fold change ratios using IBAQ 





 Majority of Proteome Remodeling in acSRSF1 HKO are Independent of the 
Transcriptome 
(A) Venn diagram showing overlap of proteins with abundance changes in acSRSF1 HKO 
model and associated genes with SRSF1 binding. A total of 126 genes with SRSF1 binding 
showed changes in abundance of the associated protein. (B) Cumulative plot of Log2 Fold 
Change of protein abundances with SRSF1 binding in associated genes. It appears protein 
abundances are independent of SRSF1 binding. (C) Venn diagram of protein abundance 
overlap with genes changing in expression, splicing, and intron retention. Significant 
overlap is seen with genes changing in expression and splicing. (D) Cumulative frequency 








 Abundances of Other SR Proteins are not Changing upon SRSF1 Knockout 
Plot of IBAQ quantification values for the detected SR proteins in acSRSF1 HKO mass 
spectrometry analysis. In agreement with the model, SRSF1 is detected to be significantly 
diminished in abundance in the knockout model. Of all the SR proteins detected, only 









 Gene Ontology Analysis of Proteins Exhibiting Differential Abundances 
Gene ontology analysis of proteins with differential abundances in acSRSF1 HKO. GO term 
enrichment analysis was performed on downregulated and upregulated proteins 
separately. Proteins that were downregulated in acSRSF1 HKO have a strong enrichment 





 Hepatic Knockout of SRSF1 Results in a Striking Downregulation of Factors 
Involved in Translation 
Heatmap showing row normalized IBAQ quantification values for detected proteins 
involved in translation regulation. The heatmap is divided into subsections involved in 
different aspects of translation. Red colored labels signify proteins which are significantly 
changing in protein abundance. The heatmap bar on the left shows the RNA-Seq 






 AcSRSF1 HKO Exhibit Increased Intron Retention Events 
Volcano plot of intron retention events identified from the acSRSF1 RNA-seq. A total of 
1,516 introns were determined to be differentially retained in the acSRSF1 HKO. Of the 
differentially retained introns, over 90% exhibited increased retention. Furthermore, a 





 Polysome Profiling Reveals Absence of Polysomes in acSRSF1 HKO 
Polysome profiling performed on control and acSRSF1 HKO hepatocytes. In control 
samples, the monosome peak appears at ~4 minutes followed by multiple polysomal 
peaks. In acSRSF1 HKO, the initial peak is left shifted in comparison to controls which may 
signify incomplete ribosomal assembly on transcripts. Furthermore, polysome peaks are 






 Global Translation is Strikingly Diminished in acSRSF1 HKO Hepatocytes 
(A) Puromycin incorporation assay was performed in hepatocytes isolated from acSRSF1 
HKO mice 2-weeks post viral induction to determine global protein synthesis. Assay was 
performed on spleens as a control tissue. (B) Quantification of nascent protein synthesis 
by normalizing lane signal of anti-Puromycin blot by the Ponceau S signal. The acSRSF1 






 Serum Lipoprotein Particle Fractionation Reveals Diminished Particles in 
acSRSF1 HKO 
Lipoprotein particle fractionation was performed on serum collected from fasted control 
or acSRSF1 HKO mice at the indicated timepoints post viral induction. Each replicate 
consists of serum pooled from 2 biological samples. HDL particles are severely diminished 
in the 4-week acSRSF1 HKO mice serum. This suggests that SRSF1 knockout in 




 Hepatocyte deficient of SRSF1 do not trigger Phosphorylation of p53 or 
eIF2α and Eventually Undergo Necroptosis  
Western blot analysis of indicated factors at the 2- and 4-week acSRSF1 HKO and 10-day 
SRSF1 HKO models. Blots depict representative samples for each group (n = 4 – 5 per 
group). Levels of p53 are decreased at the 4-week timepoint in acSRSF1 HKO and 10-day 
SRSF1 HKO model. Both models exhibit evidence of necroptosis with increased levels of 




 Loss of SRSF1 Activity in HepG2 Cells Leads to 
DNA Damage and Protein Synthesis Impairment 
 
7.1 Introduction 
Ablation of SRSF1 in hepatocytes of mouse liver results in immediate death of the 
cell and development of pathology. Molecular investigations of the SRSF1 HKO models 
has revealed widespread DNA damage which is most likely induced by pathological 
accumulation of R-loops. This is further supported by transcriptomics data which shows 
induction of DNA damage response and repair genes. Furthermore, proteomic studies of 
the SRSF1 HKO models show severe depletion of ribosomal proteins which result in 
global impairment of translation. 
To determine if this misregulation occurs in the context of human cells, publicly 
available ENCODE data was analyzed. The ENCODE project performed a large study in 
which various RNA binding proteins were knocked down in HepG2 cells and subsequent 
RNA-Seq was performed. This dataset includes knockdown of various SR proteins. 
Transcriptome analysis of this dataset was compared to the results of the acute SRSF1 
HKO to determine which aspects are conserved. In addition to SRSF1, other SR proteins 
such as SRSF3, SRSF5, SRSF7 and SRSF9 knockdowns have also been performed by 
the ENCODE consortium. These datasets have also been analyzed to find similarities 
and differences between knockdown of different SR proteins. 
Furthermore, knockdown experiments of SRSF1 in HepG2 cells was performed to 
first confirm if DNA damage and translation defects can be replicated in a cell culture 
model and secondly to further explore the mechanism of the translation defect.  
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7.2 Material and Methods 
7.2.1 Analysis of SR Protein Knockdown ENCODE Dataset 
Analysis of publicly available dataset were performed using the same pipeline 
described in Section 3.2.1. Briefly, differential gene expression analysis was performed 
using kallisto, tximport and DESeq2 packages. Differential splicing analysis was 
performed using rMATS. Gene ontology analysis was performed using the gProfiler web-
based tool. Details regarding the datasets used for this analysis can be found in Section 
9.2. Briefly, ENCODE datasets of SRSF1, SRSF3, SRSF5, SRSF7 and SRSF9 protein 
knockdown by shRNA in HepG2 cells was used for the study (Sundararaman et al. 2016).  
7.2.2 Culturing of HepG2 Cells and siRNA Mediated Knockdown 
HepG2 cell line was obtained from ATCC (catalog HB-8065) and cultured 
according to ATCC specifications. Cells were cultured in DMEM supplemented with 10% 
FBS, 2 mM glutamine, and 10 U/ml penicillin and streptomycin. For knockdown 
experiments silencer select siRNAs against SRSF1 and TP53 (Thermo Fisher Scientific 
#4392420 and #4390824) along with a negative control (Thermo Fisher Scientific 
#4390843) were purchased. Approximately 500,00 cells were seeded into a 6-well format 
and were reverse transfected with 20 nM of gene-specific siRNA oligos using RNAiMax 
(Thermo Fisher Scientific #13778075) and then transfected again using forward 
transfection 36 hours with 20 nM of siRNA. Cells were harvested after 72 hours starting 
from the initial reverse transfection. For end-point assays requiring fluorescent imaging, 




Briefly for immunofluorescent staining, cells were fixed for 10 minutes using 4% 
PFA solution followed by a PBS wash three times and then permeabilized with 0.2% 
Triton X-100 plus 1% normal goat serum (NGS) in PBS/pH 7.3 for 5 minutes on ice. Cells 
were then washed with PBS with 1% NGS and then incubated in primary antibody dilution 
for 1 hour at room temperature in a humidified chamber. This was followed by another 
wash and then incubation with secondary antibody dilution for 1 hour at room 
temperature. The cells were then washed with PBS and stained with DAPI before 
inverting the coverslip onto a glass slide with aqueous mounting media. For details on the 
dilutions of antibody used, refer to Section 9.1.9. 
Additional fluorescent assays performed on the knockdown HepG2 cells included 
a fluorescent protein synthesis assay and Annexin V staining. For the fluorescent protein 
synthesis assay, the Click-iT™ HPG Alexa Fluor™ 488 Protein Synthesis Assay Kit 
(Thermo Scientific #C10428) was used following manufacturer’s instructions. Briefly, 2 
hours prior to harvesting, culture media was replaced with methionine-free DMEM media. 
Cells were incubated in media for 1 hour before supplementing well media with 50 µM of 
ClickIT-HPG reagent. Cells were incubated for additional 1 hour before fixation. Fixed 
cells were prepared following standard kit protocol. For the fluorescent Annexin V cell 
death staining, the Dead Cell Apoptosis Kit with Annexin V FITC and PI (Thermo Scientific 
#V13242) was used following manufactures instructions. For western blot analysis, cells 
were directly lysed in 2X Laemmli buffer and then prepared for PAGE gel electrophoresis 





7.3.1 Expression of SR Proteins in HepG2 Cell Line 
Before starting analysis of the shRNA mediated knockdown of SR proteins in 
HepG2 cells, the expression levels of the SR genes in HepG2 cells were determined. This 
was achieved by plotting TPM data from all control shRNA knockdown HepG2 sample 
data available on ENCODE (Figure 7.1). Expression of SR genes were at reasonable 
expression levels with SRSF5 exhibiting the highest expression levels in HepG2. 
Interestingly, SRSF3 was found to be the most abundant protein in mice hepatocytes. 
7.3.2 Knockdown of SR Proteins Results in Significant Impact to the Transcriptome 
Next, to understand the transcriptomics changings occurring in the SRSF1, 3, 5, 
7, and 9 protein knockdowns in HepG2 datasets, differential expression and splicing 
analysis was performed. Analysis revealed a substantial number of changes in gene 
expression in splicing among the knockdowns (Figure 7.2 and 7.3). Interestingly, of all 
the SR protein knockdowns, SRSF1 showed the largest number of changes in gene 
expression and splicing (Figure 7.8). Spearman correlations were performed on the data 
to gain insight into which factors share most similarity with regards to the changes seen 
in the transcriptome (Figure 7.4). Correlation analysis shows that SRSF1 has strongest 
correlation with SRSF7. Interestingly, of the SR proteins, SRSF7 shares the most 
similarity to SRSF1 and is also has shuttling activity like SRSF1. 
Gene ontology analysis of the differentially expressed genes and spliced events 
was performed to further understand what processes are enriched in the various gene 
sets. In the upregulated gene sets for the various SR protein knockdowns, SRSF1 shows 
a strong enrichment for genes involved in cell cycle and mitosis (Figure 7.5). Interestingly 
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SRSF7 enriched for processes involved in cell adhesion and cell motility. However, in the 
downregulated gene sets, SRSF1 and SRSF7 display a strong enrichment for genes 
involved in translation and ribosomal proteins (Figure 7.6). Similar enrichment for these 
processes were seen in the acSRSF1 HKO downregulated proteins. This finding 
suggests that decrease levels of translation factors might be driven at the level of 
transcript abundance. Like the SRSF1 HKO, the differential splicing gene set does not 
exhibit strong enrichment for any biological process (Figure 7.7). 
Intron retention analysis was also performed on the shRNA mediated SR protein 
knockdown samples in HepG2. Interestingly, the SRSF1 knockdown dataset also 
displays a larger number of intron retention events with a greater portion of events 
resulting in increased retention (Figure 7.8). This is comparable to what was seen in the 
acSRSF1 HKO model. It is possible this increased retention is a result of decreased 
translation activity as the downregulated genes strongly enrich for genes involved in 
translation. 
7.3.3 Knockdown of SRSF1 Shows an Induction of a p53 Signature 
Despite the widespread DNA damage observed in SRSF1 HKO mice, activation 
of p53 was not observed. This is unexpected since p53 is known to increase in abundance 
and become activated in response to DNA damage. Two possible explanations for this 
finding are that 1) the duration of p53 activation is short lived and was therefore missed 
within the timeframes the samples were collected or 2) DNA damage induced by R-loops 
is not detected by the complex that signals to p53. To investigate p53 status in the HepG2 
SRSF1 knockdown dataset, expression of various p53 targets were examined (Figure 
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7.9). Surprisingly, multiple p53 targets are upregulated in the SRSF1 knockdown dataset 
suggesting that p53 is most likely activated. 
7.3.4 Knockdown of SRSF1 in HepG2 Recapitulates SRSF1 HKO Phenotype 
To further explore whether loss of SRSF1 in HepG2 does indeed result in DNA 
damage and inhibition of global protein synthesis, knockdown experiments using siRNA 
were performed in HepG2 cells. Efficient knockdown of SRSF1 was achieved using a 
combination of reverse transfection followed by a forward transfection after 24 hours 
(Figure 7.10). Interestingly, knockdown of SRSF1 in HepG2 shows robust upregulation 
of p53 abundance. To examine DNA damage, immunofluorescent staining for γH2A.X 
was performed on the SRSF1 knockdown HepG2 cells. In agreement with the SRSF1 
HKO findings, robust staining of γH2A.X is observed signifying DNA damage. 
Furthermore, a fluorescent based protein synthesis assay was also performed on these 
cells simultaneously. As expected, loss of SRSF1 results in decreased protein synthesis. 
7.3.5 Protein Synthesis Inhibition in SRSF1-deficient Cells is Independent of p53 
Next, to determine if the decrease in protein synthesis is caused by the activation 
of p53, a double knockdown experiment was performed where both SRSF1 and p53 were 
knocked down. Interestingly, co-knockdown of SRSF1 and p53 did not rescue the 
decreased protein synthesis phenotype (Figure 7.11). This result signifies that the 
decrease in protein synthesis is independent of p53 activation. Finally, cells were cultured 
for 96 hours and then stained with Annexin V to probe for cells undergoing cell death. As 
expected, SRSF1 knockdown cells display robust staining with Annexin V (Figure 7.11). 




Knockdown of SRSF1 in HepG2 cells corroborates the findings observed in the 
SRSF1 HKO models. Interestingly, transcriptome analysis of the SRSF1 knockdown in 
HepG2 dataset showed a strong downregulation of ribosomal protein genes and genes 
involved in translation (Figure 7.6). While SRSF1 HKO model did not show 
downregulation of genes involved in translation at the transcript level, mass spectrometry 
analysis displayed a striking downregulation in translation related factors. Furthermore, 
examining expression changes of p53 target genes, SRSF1 knockdown displayed a 
strong 53 activation signature (Figure 7.9). Indeed, western blot analysis on SRSF1 
knockdown HepG2 cells after 72 hours exhibited robust induction of p53 levels (Figure 
7.10). This was not observed in the SRSF1 HKO model. A possible explanation of this 
finding is that p53 activation is short lived and is therefore missed within the timeframes 
the hepatocytes were collected in the SRSF1 HKO models. Furthermore, levels of BAX 
and RIPK1 were not found to be induced at this timepoint. This suggests that the SRSF1 
knockdown cells at this timepoint are likely accumulating DNA damage, however, cell 
death signals have not yet been triggered.  
To confirm if DNA damage is indeed occurring after SRSF1 knockdown, 
immunofluorescent staining for γH2A.X was performed. Like the SRSF HKO, loss of 
SRSF1 in HepG2 shows presence of numerous γH2A.X foci in the nuclei confirming that 
DNA damage is present (Figure 7.11). Next, to check if protein synthesis is inhibited a 
fluorescent based assay using HPG incorporation was performed which showed striking 
reduction of protein synthesis in SRSF1 knockdown (Figure 7.11). While western blot 
analysis shows that cell death has not been triggered at the 72-hour timepoint, it is 
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expected that SRSF1 cells eventually undergo cell death. To investigate this possibility, 
SRSF1 knockdown was performed for 96 hours and then stained with Annexin V, a cell 
death marker. In agreement with expectation, longer knockdown of SRSF in HepG2 show 
prominent Annexin V signal. Therefore, SRSF1 knockdown in cells leads to eventual 
death of the cell (Figure 7.11). 
To check if the reduced protein synthesis is dependent on p53 activation, a co-
knockdown of SRSF1 and p53 experiment was performed. Results from this experiment 
show that the rescue failed with persistence of the diminished protein synthesis (Figure 
7.11). Thus, despite the activation of p53, the reduced protein synthesis response is 
independent of p53. Currently, it is unclear the exact mechanism resulting in this 
phenotype. With the widespread R-loop accumulation and DNA damage, several 
probable mechanisms can be formulated to explain the reduction in global protein 
synthesis. However, testing the exact mechanism of his irregularity is outside the scope 










 Expression of SR Proteins in HepG2 Cell Line 
Boxplot of TPM values for the various SR proteins from HepG2 cell line. TPM values were 
obtained from the control group which were treated with control shRNA. Color of the boxes 
correspond to shuttling activity of the SR protein. SRSF5 has the highest transcript 






 Gene Expression changes in SR Protein Knockdown in HepG2 
Thousands of genes show changes in gene expression upon knockdown of SR proteins 
in HepG2. SRSF1 shows the greatest number of gene expression changes. There are a 






 Splicing Changes in SR protein knockdown in HepG2 
Thousands of events undergo differential splicing upon knockdown of SR proteins in 









 SRSF1 is Most Similar to SRSF7 and SRSF9 in Regard to Expression and 
Splicing 
Heatmap of the pairwise spearman correlation values for differential expression and 
splicing in shRNA knockdown of SR proteins in HepG2. SRSF1 appears to be more 





 Knockdown of SRSF1 Triggers Upregulation of Genes Involved in Cell Cycle 
Processes 
Heatmap of Gene Ontology enrichment terms based on -log(p-value) for genes upregulated 
in the associated SR gene knockdown by shRNA. SRSF1 knockdown triggers upregulation 





 Knockdown of SRSF1 in HepG2 Results in Downregulation of Ribosomal and 
Translation Regulation Genes 
Heatmap of Gene Ontology enrichment terms based on -log(p-value) for genes 
downregulated in the associated SR gene knockdown by shRNA. SRSF1 knockdown 






 Gene Ontology Analysis for Differential Splicing in SR Gene Knockdown 
Heatmap of Gene Ontology enrichment terms based on -log(p-value) for genes with 
differential splicing in the associated SR gene knockdown by shRNA. GO term enrichment 








 Summary Table of Expression, Splicing, and Intron Retention Analysis in SR 
Gene Knockdown RNA-seq in HepG2 from the ENCODE Project 
Table showing the number of genes or events with differential expression or splicing in 
the indicated SR gene knockdown. Numbers in red signify increased expression or exon 
inclusion while blue signify decreased expression or exon skipping events. Of all SR gene 









 Knockdown of SRSF1 in HepG2 Triggers p53 Response 
Bar plot showing changes in expression estimated from RNA-seq of various p53 target 
genes upon knockdown of SRSF1 in HepG2. Multiple p53 target genes are strongly 





 Knockdown of SRSF1 in HepG2 Triggers Induction of p53 Levels 
Western blot analysis of indicated factors after 72 hours of specified siRNA treatment in 
HepG2 cells. Blots depict representative samples for each group (n = 4 – 5 per group). 
Efficient knockdown of SRFS1 is achieved. Levels of p53 are striking induced in the 
siSRSF1 treated HepG2 cells. Induction of BAX or RIPk1 are not induced signifying cell 






 Loss of SRSF1 Activity in HepG2 Induces DNA Damage, Decreased Protein 
Synthesis, and Cell Death and is Independent of p53 
HepG2 cells were cultured and treated with the indicated siRNA for 72 hours before 
performing subsequent assays. The first row of images shows representative images (n = 
5 fields by 3 replicates per group) of immunofluorescent staining for SRSF1 (red), γH2A.X 
(yellow), and nuclear (blue). The second row corresponds to nascent protein synthesis 
signal (green) of the same field using a fluorescent based ClickIT-HPG incorporation 
assay. Knockout of SRSF1 results in DNA damage and inhibition of protein synthesis. This 
response is independent of p53 activation. The last row shows representative images (n = 
5 fields by 3 replicates per group) of Annexin V staining of HepG2 cells 96 hours post 





The primary motivation of this project was to understand the role of SRSF in liver 
physiology. Investigation of its role was started by generating and studying hepatocyte-
specific SRSF1 knockout mice models. It was well established that whole-body knockouts 
of SRSF1 results in embryonic lethality in multiple model organisms. Therefore, it was a 
shocking surprise that the SRSF1 HKO mice were able to maintain viable livers at all. 
Although the livers displayed significant inflammation and damage, SRSF1 HKO mice 
must have some degree of liver function to be able to survive for as long as they do. Our 
assumption that SRSF1 was efficiently knocked out of the hepatocytes in this model was 
incorrect. It was not realized until later that hepatocytes were able to subvert the knockout 
of SRSF1 by repressing the expression of the Cre transgene. Due to this incorrect 
understanding of the model, the initial working hypothesis explaining the observed 
phenotype was that loss of SRSF1 was causing changes in the transcriptome resulting in 
the observed inflammation, steatosis, and fibrosis (Figure 8.1).  
 
 




As a result of this initial working hypothesis, much of the efforts in the beginning 
were focused on studying the irregularities in the transcriptome. This resulted in 
performing multiple RNA-seq and eCLIP-seq experiments. However, these studies did 
not provide viable explanations to the phenotype that was observed in the SRSF1 HKO 
model. This eventually led to the development of the second SRSF1 knockout model 
which is referred to as the Acute SRSF1 HKO model. The motivation behind developing 
this model was that an acute viral-mediated knockout of SRSF1 in an adult animal will 
provide additional temporal control over the deletion of SRSF1. We reasoned that a major 
limitation of the SRSF1 HKO model was that pathological changes were occurring too 
quickly. Therefore, insight into the pathological mechanism was being obscured due to 
the overwhelming secondary effects which was masking the primary effectors. To 
overcome this issue, the acSRSF1 HKO will allow for isolation of hepatocytes before any 
secondary changes could take place. While this model provided the ability to study 
SRSF1 knockout prior to secondary changes, like the SRSF1 HKO, transcriptome studies 
on this model failed to offer any additional insights into the liver pathology of HKOs. 
Progress into the mechanistic understanding began to change when the 
immunofluorescent staining assay for SRSF1 in liver tissue was developed. This assay 
allowed for identifying the cells expressing SRSF1 within the intact liver tissue. 
Shockingly, when this assay was performed on the SRSF1 HKO tissue it was clear that 
the liver was repopulating the tissue with SRSF1-expressing hepatocytes. It was 
eventually realized that this was due to proliferation of hepatocytes where Cre expression 
is suppressed thus allowing SRSF1 to stay intact. This phenomenon is also not novel and 
has been observed previously with the generation of the hepatocyte-specific Dicer1 
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knockout mice (Sekine et al. 2009). Like SRSF1 HKO, efficient deletion of Dicer1 was 
achieved in young mice liver followed by repopulation with Dicer1-expressing 
hepatocytes. Insight into the mechanism of how the livers can bypass the knockout was 
shown by Duncan, et al 2012. They show that because of selection pressure, expansion 
of knockout resistant aneuploid hepatocytes occurs. In the case of SRSF1 HKO, it is likely 
that the Cre transgene locus is being lost leading to the generation of SRSF1 knockout 
resistant hepatocytes. With this finding it was understood that SRSF1 was vital the 
functioning of the cell and loss of its activity was resulting in immediate death of the cell. 
At this point, extensive review of the past literature on SRSF1 was performed to 
identify any studies which investigated its knockout in a system. This literature review led 
to a 2005 paper by Li and Manley where they developed a tet responsive SRSF1 
knockdown system in DT40 cells, a chicken B cell line. Surprisingly, they discovered that 
after SRSF1 depletion, the cultures eventually began to grow cells that were resistant to 
tet-mediated knockdown. They ultimately discovered that loss of SRSF1 resulted in the 
accumulation of R-loops leading to subsequent DNA damage. It was quickly realized that 
a similar phenomenon must be occurring in the SRSF1 HKO models. Indeed, probing of 
SRSF1 HKO tissue sections with γH2A.X, a well-established DNA damage marker, 
showed robust signal within the nuclei. Furthermore, dot blot assay for the presence of 
R-loops revealed a remarkable accumulation within the SRSF1 HKO. Therefore, loss of 
SRSF1 is leading to R-loop accumulation with subsequent DNA damage. 
An additional observation made during phenotypic characterization of the SRSF1 
HKO model was that these mice exhibited significant impairment of global translation. 
Proteomics analysis revealed striking downregulation of ribosomal proteins and factors 
144 
 
involved in translation. Moreover, polysome profiling showed absence of polysomes while 
a puromycin incorporation assay revealed diminished protein synthesis upon knockout of 
SRSF1. A possible explanation for this finding is that the extensive DNA damage in 
SRSF1 HKO is resulting in activation of p53 which triggers the subsequent shutdown of 
global translation. However, western blot analysis of SRSF1 HKO does not indicate 
activation of p53. Interestingly, when knockdown is performed in HepG2 cells, activation 
of p53 is observed along with DNA damage and inhibition of protein synthesis. A double 
knockdown experiment was conducted where both SRSF1 and p53 were simultaneously 
depleted to check if it could rescue the translation shutdown response. The findings from 
this experiment indicated that the protein synthesis inhibition following SRSF1 knockdown 
is independent of p53. 
 To reiterate, this project’s main goal was to understand the role of SRSF1 in liver 
physiology. Investigation of the SRSF1 HKO model led to the understanding that SRSF1 
is vital for the overall physiology of all eukaryotic cells. This is due to its crucial role in 
protecting genomic DNA by preventing the formation of deleterious R-loops between 
nascent RNAs and template DNA during transcription. In the setting of SRSF1 knockout, 
R-loop accumulation induces DSBs which leads to inhibition of global translation and 
subsequent death of the cell. In the context of the liver tissue, widespread hepatocyte 
death results in hepatic failure, which encompasses decreased accumulation of 
triglycerides within the tissue, failed formation of lipoprotein particles, and impaired levels 




 Proposed Mechanism of Hepatocyte Response Upon SRSF1 Knockout 
Loss of SRSF1 results in increased accumulation of unresolved R-Loops resulting in DNA 
damage through double stranded breaks. The genome instability triggers a response 
resulting in global inhibition of translation. Without SRSF1 the cell is not able to resolve 
the irregularities in gene expression and results in subsequent failure of the cell.  
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 Supplementary Information 
 
9.1 Supplemental Protocols 
9.1.1 Genotyping of SRSF1 HKO Mice Model Using Tail Clippings 
Mouse genotyping was performed on genomic DNA isolated from tail clippings. 
Mice tails were lysed using 100 uL of DirectPCR tail lysis buffer (Viagen Biotech) 
supplemented with Proteinase K (20 µg) and incubated overnight at 55 °C. The following 
day, lysed tails were incubated at 100 °C for 20 minutes to heat inactivate Proteinase K. 
The mixture was then spun down to pellet insoluble debris and 1 µL of the supernatant 
containing genomic DNA was used to setup PCR reactions. Primers, reaction setup and 
cycling protocol are detailed in the following tables.  




Forward Primer (5’ → 3’) Reverse Primer (5’ → 3’) 
SRSF1 Flox GGGACTAATGTGGGAAGAATG AACCTAAACTATTGCTCCCATCTG 
Albumin-CRE GAAACCTGATGGACATGTTCAGG AGTGCGTTCGAACGCTAGAGCCTGT 
 
Table 9.2: SRSF1 Genotyping PCR Reaction Component Setup 
SRSF1 Flox Genotyping Reaction Setup 
Components Volume/Reaction (μL) 
10X PCR Buffer 2 
50 mM MgCl2 0.6 
10mM dNTPs 0.4 
Platinum Taq 0.08 
Forward Primer, 10 µM 0.5 








Table 9.3: AlbCre Genotyping PCR Reaction Component Setup 
AlbCre Genotyping Reaction Setup 
Components Volume/Reaction (μL) 
5X Taq Mix 5 
Forward Primer, 10 µM 0.5 





Table 9.4: SRSF1 Flox Genotyping Reaction Thermocycling Conditions 
SRSF1 Flox Genotyping PCR Thermocycling 
Conditions 
Step Temperature Time 















Final Extension 72°C 2 minutes 
Hold 4-10°C  
 
Table 9.5: AlbCre Genotyping Reaction Thermocycling Conditions 
AlbCre Genotyping PCR Thermocycling Conditions 
Step Temperature Time 








Final Extension 72°C 3 minutes 
Hold 4°C  
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Genotyping reactions were then separated on a 5% PAGE gel, stained with 
ethidium bromide, and visualized using the ChemiDoc XRS+. The following gel images 
depicts a representative genotyping gel and its interpretation.  
 
 SRSF1 HKO Mice Model Genotyping Gel 
SRSF1 HKO mice model genotyping reactions separated on 5% PAGE gel.  
9.1.2 Purification of Hepatocytes from Mice Liver 
Hepatocytes were isolated and purified using the Two-Step Collagenase Perfusion 
Technique (W. C. Li, Ralphs, and Tosh 2010). Mice were first anesthesized with 
isoflurane and then secured to a surgery pad with the ventral side up. A “U” shaped 
incision was made on the abdomen to expose the liver. The liver was then perfused 
through the portal vein with 50 ml of wash buffer containing 1X Hanks Balanced Salt 
Solution (HBSS) and 1 mM EDTA (pH 8.0), without calcium and magnesium salts. 
Following this, the livers were perfused using 50 ml of digestion buffer containing 1X 
HBSS, 0.5 mM CaCl2, 40 µg/mL soybean trypsin inhibitor, and 60 U/mL of Collagenase 
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Type I from Worthington. The perfused liver was carefully excised out from the abdomen 
and transferred into a petri dish containing 1X HBSS. Using cell scrapers, the tissue was 
carefully massaged to release the cells from the capsule. The crude cell prep was then 
filtered through a 40 µm mesh filter and the resulting single cell suspension was 
centrifuged at 50 g for 5 minutes at 4 °C. The supernatant containing non-parenchymal 
cells (NPCs) and dead hepatocytes was discarded while the pellet containing live 
hepatocytes were resuspended in fresh 1X HBSS. The centrifugation wash was repeated 
two additional times before being aliquoted into 1.5 mL microcentrifuge tubes, flash frozen 
in liquid nitrogen and stored in -80 °C until further use.  
To assess whether efficient separation of hepatocytes and NPCs was achieved, 
RT-PCR followed by gel electrophoresis assay was performed as described in Section 
9.1.6 for various hepatocyte and NPC markers. The following figure demonstrates that 
efficient separation of hepatocyte and NPC cell populations was achieved using this 
protocol (Figure 9.2). Specifically, multiple NPC markers are absent in the hepatocyte 




 Assessment of Hepatocyte Isolation from Mice Whole Liver Tissue 
Separation of hepatocytes and NPCs was achieved with significant enrichment for the 
associated population. Hepatocyte makers: Alb, TDO; NPC markers: Gfap, F4/80, Vim, 
Ck19, vWF; Control marker: Gapdh. 
 
9.1.3 Protein Isolation from Tissue and Western Blotting Analysis 
Total proteins were isolated from ~50 mg of snap frozen liver tissue or purified cell 
pellet by homogenizing in 400 µL of cold homogenization buffer containing 10 mM HEPES 
(pH 7.5), 0.32M Sucrose, 5 mM EDTA, 1% SDS, 5 µM MG132 and Pierce Protease 
Inhibitors (1 tablet per 10 mL of buffer, Catalog # A32953). Samples were sonicated in a 
water bath to shear DNA and clarified by centrifugation. Protein concentration was 
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determined using the Pierce™ BCA Protein Assay Kit (Thermo Scientific). Protein 
lysates were diluted to 5 mg/mL and then boiled in 1X Laemmli buffer at 100 °C for 10 
minutes. Once boiled, samples were cooled to room temperature and ~50 µg of proteins 
were resolved on a 10% SDS-PAGE gel and transferred using a wet transfer setup onto 
a PVDF membrane with 0.45 µm pore size (Immobilon, Millipore). Membranes were 
blocked using Tris-buffered saline containing 5% nonfat dry milk and 0.1% Tween 20 
(TBST). After blocking, membranes were incubated with primary antibody overnight at 
4°C. The membranes were then washed with TBST to remove any unbound primary 
antibody followed by incubation with an appropriate horseradish peroxidase-conjugated 
secondary antibody for two hours. Membranes went through a final TBST wash and then 
visualized on the ChemiDoc XRS+ using the Clarity Western ECL kit (BioRad). Refer to 
Section 9.1.9 for details on antibody source and dilutions. 
9.1.4 Histological, Immuno-histochemistry and fluorescence Staining 
For paraffin embedding, liver tissues were harvested and immediately fixed in 10% 
neutral-buffered formalin overnight at 4 °C. Fixed tissues were then processed in a series 
of solvents starting from ethanol solutions, to xylenes, and finally embedded into paraffin 
wax. Paraffin embedded tissues were cut into 5 µm thick sections using a microtome. The 
sections were placed onto charged microscope slides and allowed to air dry overnight 
before performing histological staining. For frozen tissue embedding, a piece of fresh and 
unfixed tissue was submerged into a plastic mold filled with OCT medium (Tissue-Tek, 
Sakura) and frozen using liquid nitrogen. Using a cryostat, sections were cut into 10 µm 
thick sections and transferred onto a room temperature microscope slide. The slides with 
frozen tissue sections were stored at -80 °C prior to staining. 
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• Hematoxylin and Eosin Staining 
Slides with paraffin embedded tissue sections were deparaffinized in xylene and 
then rehydrated by incubating them in a decreasing gradient of ethanol solutions with a 
final incubation in distilled water. Once rehydrated, the sections were stained with 
Modified Harris Hematoxylin Solution (7211 Richard-Allan Scientific) for 2 minutes. It was 
then briefly rinsed in water and then stained with Eosin-Y Solution (7111 Richard-Allan 
Scientific) for 1 minute. The stained sections were then dehydrated by incubating the 
slides in an increasing gradient of ethanol solutions with a final incubation in xylene. Once 
dehydrated the slides were mounted with Permount (Fisher Scientific) mounting media 
and coverslip. 
• Sirius Red Staining 
Slides with paraffin embedded tissue sections were deparaffinized and rehydrated 
as explained in the Hematoxylin and Eosin Staining protocol. Slides were then incubated 
in Picro-sirius red solution (0.1% w/v Direct Red 80 in saturated aqueous solution of picric 
acid) for 1 hour. They were then briefly rinsed in two changes of 0.5% acetic acid solution. 
The slides were then dehydrated and mounted in the same manner as described in the 
the Hematoxylin and Eosin Staining protocol. 
• Oil Red O Staining 
Frozen tissue sections were taken out from -80 °C and allowed to air dry for about 
5 minutes. They were then fixed in 10% Neutral-buffered formalin solution for 10 minutes 
at room temperature. Slides were then briefly rinsed in tap water and then 60% 
isopropanol solution. Slides were then stained with freshly prepared Oil Red O solution 
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(0.3% w/v Oil Red O in 60% isopropanol) for 15 minutes. Once stained, the slides were 
rinsed in 60% isopropanol solution and gently counterstained with Modified Harris 
Hematoxylin. Slides were rinsed with distilled water and mounted using CC mount (C9368 
Sigma) and coverslip. Slides were allowed to dry before imaging. 
• Immunohistochemistry (IHC) and Immunofluorescent (IF) Staining 
Slides with paraffin embedded tissue sections were deparaffinized and rehydrated as 
explained in the Hematoxylin and Eosin Staining protocol. Slides were then antigen 
retrieved in buffer containing 10 mM Tris, 1 mM EDTA, 0.05% Tween 20, pH 8.0 for 5 
minutes at 120 °C using a slow cooker. The sections were then incubated in wash buffer 
containing 1X TBS and 0.025% Triton X-100 and then blocked using 1X TBS, 10% 
Normal Goat Serum (NGS) and 1% BSA for 2 hours at room temperature (RT). Primary 
antibodies were applied to the sections at standardized concentrations and incubated 
overnight at 4 °C. Following this, the sections were incubated in wash buffer, and 
secondary HRP-conjugated or fluorescent antibodies were applied for 1 hour at RT for 
IHC or IF, respectively. 
IHC - The sections were washed in 1X TBS and then developed using a DAB Peroxidase 
Substrate kit (Vector Laboratories) for approximately 5 minutes. Sections were 
counterstained with hematoxylin, dehydrated into xylenes, and then mounted using 
Permount.  
IF – The sections were washed in 1X TBS and then stained for the nucleus using ToPro3 
for 15 minutes at RT. The sections were then cover slipped using CC aqueous mounting 
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media. All sections were imaged on a Zeiss LSM 710 microscope at IGB core facility, 
UIUC. All antibodies used, and respective dilutions are listed in Section 9.1.9. 
9.1.5 Total RNA Isolation and Real Time Quantitative RT-PCR (qRT-PCR) Analysis 
Total RNA was isolated from about 50 mg of snap frozen liver tissue or snap frozen 
cells from 6-well culture plates with TRIzol (Invitrogen) using the protocol described in the 
manual. Quality of the RNA was assessed by running about 1 µg of RNA on a bleach gel 
to evaluate the 28S and 18S bands (Aranda, LaJoie, and Jorcyk 2012). Approximately 5 
µg of RNA was then reverse-transcribed into cDNA using the Maxima Reverse 
Transcriptase (Thermo Fisher Scientific) following manufactures protocol. Relative gene 
expression analysis was performed with ~50 ng of cDNA per reaction using a SYBR® 
Green™ based assay for Real-Time Quantitative Reverse Transcription PCR (qRT-PCR). 
The following table details the cycling conditions for the reaction. 
Primer sets used to assay the various genes in the study are listed in Primer 
Sequence Table in Section 9.1.8. Using 36B4 as a loading control, relative gene 
expression compared to the control group was calculated by the double Ct method (Livak 
and Schmittgen 2001). 
9.1.6 Reverse Transcription PCR followed by Gel Electrophoresis Analysis 
Total RNA and subsequent preparation of cDNA was performed as specified in 
Section 9.1.5. The cDNA was diluted to 25 ng μl−1 with nuclease free water from which 1 
µL would be used for PCR reactions. PCR reactions were setup using Taq DNA 
Polymerase (NEB #M0237) along with forward and reverse primers to a final 
concentration of 0.2 µM. Cycling conditions used for the PCR reaction are as follows; 
Initial denaturation at 95 °C for 30 seconds, 30 cycles consisting of denaturation at 95 °C 
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for 20 seconds, annealing at 60 °C for 30 seconds, and extension at 68 °C for 30 seconds, 
and a final extension at 68 °C for 5 minutes. For visualization, 10 µL of reaction mixture 
was mixed with loading dye and then resolved on a 5% PAGE gel, stained in an ethidium 
bromide bath, and then imaged using ChemiDoc XRS+. 
9.1.7 TUNEL Staining on Tissue Sections for Apoptosis 
TUNEL staining was performed on paraffin tissue sections that were deparaffinized 
and rehydrated as specified in the Hematoxylin and Eosin Staining protocol in Section 
9.1.4. Staining was performed with the In-Situ Cell Death Detection Kit, Fluorescein 
(Sigma Cat# 11684795910) using manufacturer protocol. Briefly, rehydrated tissue 
sections were permeabilized and then labelled using the TUNEL reaction mixture from 
the kit. The sections were incubated with the reaction mixture for 1 hour at 37 °C in a 
humidified chamber. Slides were then rinsed with PBS three times, counterstained for 
nucleus, and mounted with coverslip. For positive control, the section was treated with 20 





9.1.8 Primer Sequences 
Table 9.6: Forward and Reverse Primer Sequences of Indicated Genes 
Gene Forward Primer (5' → 3') Reverse Primer (5' → 3') 
Product 
Size 
36b4 AGATGCAGCAGATCCGCAT GTTCTTGCCCATCAGCACC 59 
Alb GCTCGTCTGAGCCAGACATT CAAGTTCCGCCCTGTCATCT 133 
Ck19 GGGGGTTCAGTACGCATTGG GAGGACGAGGTCACGAAGC 113 
Cre GCATTTCTGGGGATTGCTTA ATTCTCCCACCGTCAGTACG 95 
F4/80 TGGGATGCATAATCGCTGCT CCTCAGAACCCACAGTGTCC 124 
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 123 
Gfap CGGAGACGCATCACCTCTG TGGAGGAGTCATTCGAGACAA 120 
Tdo ATGAGTGGGTGCCCGTTTG GGCTCTGTTTACACCAGTTTGAG 105 
Vim CGTCCACACGCACCTACAG GGGGGATGAGGAATAGAGGCT 74 
vWF CTTCTGTACGCCTCAGCTATG GCCGTTGTAATTCCCACACAAG 125 






9.1.9 Antibodies and Dilutions 
















IF - 1:500 







IF - 1:500 





WB - 1:5000 







IF - 1:500 







IF - 1:500 
Thermo Fisher 
Scientific, 35561 
BAX Rabbit Primary WB - 1:5000 Abcam, ab32503 
Beta-actin Rabbit Primary WB - 1:5000 




Mouse Primary DB - 1:5000 Abcam, ab256361 
ds DNA Mouse Primary DB - 1:5000 Abcam, ab27156 
eIF2α Rabbit Primary WB - 1:5000 
Cell Signaling Technology, 
9722 
Hnf4a Mouse Primary IF - 1:500 Abcam, ab41898 
Hnf4a Rabbit Primary IF - 1:500 
Cell Signaling Technology, 
3113 
Ki67 Mouse Primary IHC - 1:250 BD Biosciences, 550609 
p53 Rabbit Primary WB - 1:5000 Abcam, ab131442 
phospho-eIF2α 
(S51) 
Rabbit Primary WB - 1:5000 
Cell Signaling Technology, 
9721 













Rabbit Primary IF - 1:500 Abcam, ab11174 
phospho-p53 (S15) Rabbit Primary WB - 1:5000 Abcam, ab1431 
RIP Rabbit Primary WB - 1:5000 Abcam, ab106393 
SRSF1 Rabbit Primary 
IF - 1:500,         
WB - 1:5000 
Abcam, ab129108 
SRSF1 (103) Mouse Primary 
IF - 1:500,          
WB - 1:5000 
Invitrogen, 32-4600 
TBP Mouse Primary WB - 1:10000 
Thermo Fisher Scientific, 
MA5-14739 





The following table provides details of the RNA-Seq data generated and analyzed 
for the current study. All raw RNA-seq data files are available for download from NCBI 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession numbers 
GSE147005. 








GSM4412193  SRSF1 HKO AlbCre +/- NA 10 days 1 101964963 
GSM4412194  SRSF1 HKO AlbCre +/- NA 10 days 2 110546221 
GSM4412195  SRSF1 HKO 
SRSF1 fl/fl; 
AlbCre +/- 
NA 10 days 1 116181095 
GSM4412196  SRSF1 HKO 
SRSF1 fl/fl; 
AlbCre +/- 
NA 10 days 2 117337934 
GSM4412197  SRSF1 HKO AlbCre +/- NA 5 weeks 1 117680056 
GSM4412198  SRSF1 HKO AlbCre +/- NA 5 weeks 2 116619589 
GSM4412199  SRSF1 HKO 
SRSF1 fl/fl; 
AlbCre +/- 
NA 5 weeks 1 115650894 
GSM4412200  SRSF1 HKO 
SRSF1 fl/fl; 
AlbCre +/- 














































The following table provides details of the ENCODE datasets analyzed for the 
investigations in Chapter 7. These datasets are publicly available from the web portal at 
www.encodeproject.org.  







SRSF7-human ENCSR017PRS paired-end 
fastq, bam, 
bigWig 
SRSF1-human ENCSR094KBY paired-end 
fastq, bam, 
bigWig 
SRSF9-human ENCSR597XHH paired-end 
fastq, bam, 
bigWig 
SRSF3-human ENCSR376FGR paired-end 
fastq, bam, 
bigWig 
SRSF5-human ENCSR447UCG paired-end 
fastq, bam, 
bigWig 























Anczuków, Olga, Avi Z Rosenberg, Martin Akerman, Shipra Das, Lixing Zhan, Rotem 
Karni, Senthil K Muthuswamy, and Adrian R Krainer. 2012. “The Splicing Factor 
SRSF1 Regulates Apoptosis and Proliferation to Promote Mammary Epithelial Cell 
Transformation.” Nature Structural & Molecular Biology 19 (2): 220–28. 
https://doi.org/10.1038/nsmb.2207. 
Aranda, Patrick S, Dollie M LaJoie, and Cheryl L Jorcyk. 2012. “Bleach Gel: A Simple 
Agarose Gel for Analyzing RNA Quality.” Electrophoresis 33 (2): 366–69. 
https://doi.org/10.1002/elps.201100335. 
Asrih, Mohamed, and François R. Jornayvaz. 2015. “Metabolic Syndrome and 
Nonalcoholic Fatty Liver Disease: Is Insulin Resistance the Link?” Molecular and 
Cellular Endocrinology. Elsevier. https://doi.org/10.1016/j.mce.2015.02.018. 
Belotserkovskii, Boris P, Jane Hae, Soo Shin, and Philip C Hanawalt. 2017. “Strong 
Transcription Blockage Mediated by R-Loop Formation within a G-Rich 
Homopurine-Homopyrimidine Sequence Localized in the Vicinity of the Promoter.” 
Nucleic Acids Research 45 (11): 6589–99. https://doi.org/10.1093/nar/gkx403. 
Ben-Moshe, Shani, and Shalev Itzkovitz. 2019. “Spatial Heterogeneity in the 
Mammalian Liver.” Nature Reviews Gastroenterology and Hepatology. 
https://doi.org/10.1038/s41575-019-0134-x. 
Bolger, Anthony M, Marc Lohse, and Bjoern Usadel. 2014. “Genome Analysis 




Bray, Nicolas L, Harold Pimentel, Páll Melsted, and Lior Pachter. 2016. “Near-Optimal 
Probabilistic RNA-Seq Quantification.” Nature Biotechnology 34 (5): 525–27. 
https://doi.org/10.1038/nbt.3519. 
Chen, Qing Rong, Rosemary Braun, Ying Hu, Chunhua Yan, Elizabeth M. Brunt, Daoud 
Meerzaman, Arun J. Sanyal, and Kenneth Buetow. 2013. “Multi-SNP Analysis of 
GWAS Data Identifies Pathways Associated with Nonalcoholic Fatty Liver 
Disease.” PLoS ONE 8 (7): 1–11. https://doi.org/10.1371/journal.pone.0065982. 
Cyphert, T. J., A. L. Suchanek, B. N. Griffith, and L. M. Salati. 2013. “Starvation Actively 
Inhibits Splicing of Glucose-6-Phosphate Dehydrogenase MRNA via a Bifunctional 
ESE/ESS Element Bound by HnRNP K.” Biochimica et Biophysica Acta - Gene 
Regulatory Mechanisms 1829 (9): 905–15. 
https://doi.org/10.1016/j.bbagrm.2013.04.009. 
Dara, Lily, Cheng Ji, and Neil Kaplowitz. 2011. “The Contribution of Endoplasmic 
Reticulum Stress to Liver Diseases.” Hepatology 53 (5): 1752–63. 
https://doi.org/10.1002/hep.24279. 
Das, Shipra, Olga Anczuków, Martin Akerman, and Adrian R. Krainer. 2012. “Oncogenic 
Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYC.” Cell Reports 1 
(2): 110–17. https://doi.org/10.1016/j.celrep.2011.12.001. 
Das, Shipra, and Adrian R Krainer. 2014. “Emerging Functions of SRSF1, Splicing 




Davidson, Nicholas O., and Gregory S. Shelness. 2000. “Apolipoprotein B: MRNA 
Editing, Lipoprotein Assembly, and Presecretory Degradation.” Annual Review of 
Nutrition. Annual Reviews 4139 El Camino Way, P.O. Box 10139, Palo Alto, CA 
94303-0139, USA. https://doi.org/10.1146/annurev.nutr.20.1.169. 
Dobin, Alexander, Carrie A Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, 
Sonali Jha, Philippe Batut, Mark Chaisson, and Thomas R Gingeras. 2013. 
“Sequence Analysis STAR: Ultrafast Universal RNA-Seq Aligner” 29 (1): 15–21. 
https://doi.org/10.1093/bioinformatics/bts635. 
Dong, Gaochao, Qixing Mao, Wenjie Xia, Youtao Xu, Jie Wang, Lin Xu, and Feng 
Jiang. 2016. “PKM2 and Cancer: The Function of PKM2 beyond Glycolysis 
(Review).” Oncology Letters. Spandidos Publications. 
https://doi.org/10.3892/ol.2016.4168. 
Duncan, Andrew W. 2013. “Aneuploidy, Polyploidy and Ploidy Reversal in the Liver.” 
Seminars in Cell and Developmental Biology. Academic Press. 
https://doi.org/10.1016/j.semcdb.2013.01.003. 
Duncan, Andrew W, Amy E Hanlon Newell, Weimin Bi, Milton J Finegold, Susan B 
Olson, Arthur L Beaudet, and Markus Grompe. 2012. “Aneuploidy as a Mechanism 
for Stress-Induced Liver Adaptation.” Journal of Clinical Investigation 122 (9): 
3307–15. https://doi.org/10.1172/JCI64026. 
Fagan-Solis, Katerina D., Dennis A. Simpson, Rashmi J. Kumar, Luciano G. Martelotto, 
164 
 
Lisle E. Mose, Naim U. Rashid, Alice Y. Ho, et al. 2020. “A P53-Independent DNA 
Damage Response Suppresses Oncogenic Proliferation and Genome Instability.” 
Cell Reports. https://doi.org/10.1016/j.celrep.2020.01.020. 
Folch, Jordi, M Lees, and G H Sloane. 1957. “A Simple Method for the Isolation and 
Purification of Total Lipides from Animal Tissues.” The Journal of Biological 
Chemistry 226 (1): 497–509. http://www.jbc.org/. 
Frevert, Ute, Sabine Engelmann, Sergine Zougbédé, Jörg Stange, Bruce Ng, Kai 
Matuschewski, Leonard Liebes, and Herman Yee. 2005. “Intravital Observation of 
Plasmodium Berghei Sporozoite Infection of the Liver.” Edited by Thomas Egwang. 
PLoS Biology 3 (6): e192. https://doi.org/10.1371/journal.pbio.0030192. 
Galgani, J, and E Ravussin. 2008. “Energy Metabolism, Fuel Selection and Body 
Weight Regulation.” International Journal of Obesity. 
https://doi.org/10.1038/ijo.2008.246. 
Gebhardt, Rolf. 1992. “Metabolic Zonation of the Liver: Regulation and Implications for 
Liver Function.” Pharmacology and Therapeutics. Pergamon. 
https://doi.org/10.1016/0163-7258(92)90055-5. 
Goodman, Craig A., Danielle M. Mabrey, John W. Frey, Man Hing Miu, Enrico K. 
Schmidt, Philippe Pierre, and Troy A. Hornberger. 2010. “Novel Insights into the 
Regulation of Skeletal Muscle Protein Synthesis as Revealed by a New 




Goodman, Craig A, and Troy A Hornberger. 2013. “Measuring Protein Synthesis with 
SUnSET: A Valid Alternative to Traditional Techniques?” Exercise and Sport 
Sciences Reviews 41 (2): 107–15. https://doi.org/10.1097/JES.0b013e3182798a95. 
Hir, Hervé Le, Jérôme Saulière, and Zhen Wang. 2016. “The Exon Junction Complex as 
a Node of Post-Transcriptional Networks.” Nature Reviews Molecular Cell Biology. 
Nature Publishing Group. https://doi.org/10.1038/nrm.2015.7. 
Hocine, Sami, Robert H Singer, and David Grünwald. 2010. “RNA Processing and 
Export.” Cold Spring Harbor Perspectives in Biology 2 (12): a000752. 
https://doi.org/10.1101/cshperspect.a000752. 
Howard, Jonathan M, and Jeremy R Sanford. 2015. “THE RNAissance Family: SR 
Proteins as Multifaceted Regulators of Gene Expression.” Wiley Interdiscip Rev 
RNA 6 (1): 93–110. https://doi.org/10.1002/wrna.1260. 
Huang, Yingqun, Therese A Yario, and Joan A Steitz. 2004. “A Molecular Link between 
SR Protein Dephosphorylation and MRNA Export.” Proceedings of the National 
Academy of Sciences 101 (26): 9666–70. 
https://doi.org/10.1073/pnas.0403533101. 
Hussain, M. Mahmood, Paul Rava, Meghan Walsh, Muhammad Rana, and Jahangir 
Iqbal. 2012. “Multiple Functions of Microsomal Triglyceride Transfer Protein.” 
Nutrition and Metabolism. BioMed Central. https://doi.org/10.1186/1743-7075-9-14. 
Krainer, A R, G C Conway, and D Kozak. 1990. “Purification and Characterization of 




Kuleshov, Maxim V, Matthew R Jones, Andrew D Rouillard, Nicolas F Fernandez, 
Qiaonan Duan, Zichen Wang, Simon Koplev, et al. 2016. “Enrichr: A 
Comprehensive Gene Set Enrichment Analysis Web Server 2016 Update.” Nucleic 
Acids Research 44 (W1): W90–97. https://doi.org/10.1093/nar/gkw377. 
Lee, Ursula E., and Scott L. Friedman. 2011. “Mechanisms of Hepatic Fibrogenesis.” 
Best Practice and Research: Clinical Gastroenterology 25 (2): 195–206. 
https://doi.org/10.1016/j.bpg.2011.02.005. 
Lee, Yeon, and Donald C. Rio. 2015. “Mechanisms and Regulation of Alternative Pre-
MRNA Splicing.” Annual Review of Biochemistry. https://doi.org/10.1146/annurev-
biochem-060614-034316. 
Li, Wan Chun, Kate L. Ralphs, and David Tosh. 2010. “Isolation and Culture of Adult 
Mouse Hepatocytes.” Methods in Molecular Biology (Clifton, N.J.). 
https://doi.org/10.1007/978-1-59745-019-5_13. 
Li, Xialu, and James L. Manley. 2005. “Inactivation of the SR Protein Splicing Factor 
ASF/SF2 Results in Genomic Instability.” Cell 122 (3): 365–78. 
https://doi.org/10.1016/j.cell.2005.06.008. 
Li, Xialu, Tianhui Niu, and James L. Manley. 2007. “The RNA Binding Protein RNPS1 




Liu, Cheng, Qing Tao, Mingyu Sun, Jim Z Wu, Wengang Yang, Ping Jian, Jinghua 
Peng, Yiyang Hu, Chenghai Liu, and Ping Liu. 2010. “Kupffer Cells Are Associated 
with Apoptosis, Inflammation and Fibrotic Effects in Hepatic Fibrosis in Rats.” 
Laboratory Investigation 90 (12): 1805–16. 
https://doi.org/10.1038/labinvest.2010.123. 
Livak, K J, and T D Schmittgen. 2001. “Analysis of Relative Gene Expression Data 
Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method.” Methods 
(San Diego, Calif.) 25 (4): 402–8. https://doi.org/10.1006/meth.2001.1262. 
Long, Jennifer C., and Javier F. Caceres. 2009. “The SR Protein Family of Splicing 
Factors: Master Regulators of Gene Expression.” The Biochemical Journal 417 (1): 
15–27. https://doi.org/10.1042/BJ20081501. 
Love, Michael I., Wolfgang Huber, and Simon Anders. 2014. “Moderated Estimation of 
Fold Change and Dispersion for RNA-Seq Data with DESeq2.” Genome Biology 15 
(12): 550. https://doi.org/10.1186/s13059-014-0550-8. 
Mabin, Justin W., Lauren A. Woodward, Robert D. Patton, Zhongxia Yi, Mengxuan Jia, 
Vicki H. Wysocki, Ralf Bundschuh, and Guramrit Singh. 2018. “The Exon Junction 
Complex Undergoes a Compositional Switch That Alters MRNP Structure and 
Nonsense-Mediated MRNA Decay Activity.” Cell Reports 25 (9): 2431-2446.e7. 
https://doi.org/10.1016/J.CELREP.2018.11.046. 
Mah, L. J., A El-Osta, and T C Karagiannis. 2010. “Γh2AX: A Sensitive Molecular 
Marker of DNA Damage and Repair.” Leukemia. https://doi.org/10.1038/leu.2010.6. 
168 
 
Medina, Marisa Wong, Feng Gao, Devesh Naidoo, Lawrence L. Rudel, Ryan E. Temel, 
Allison L. McDaniel, Stephanie M. Marshall, and Ronald M. Krauss. 2011. 
“Coordinately Regulated Alternative Splicing of Genes Involved in Cholesterol 
Biosynthesis and Uptake.” Edited by Ying Xu. PLoS ONE 6 (4): e19420. 
https://doi.org/10.1371/journal.pone.0019420. 
Michlewski, Gracjan, Jeremy R. Sanford, and Javier F. Cáceres. 2008. “The Splicing 
Factor SF2/ASF Regulates Translation Initiation by Enhancing Phosphorylation of 
4E-BP1.” Molecular Cell 30 (2): 179–89. 
https://doi.org/10.1016/j.molcel.2008.03.013. 
Morales, Julio C, Patricia Richard, Praveen L Patidar, Edward A Motea, Tuyen T Dang, 
James L Manley, and David A Boothman. 2016. “XRN2 Links Transcription 
Termination to DNA Damage and Replication Stress.” PLoS Genetics 12 (7). 
https://doi.org/10.1371/journal.pgen.1006107. 
Müller-McNicoll, Michaela, Valentina Botti, Antonio M. de Jesus Domingues, Holger 
Brandl, Oliver D. Schwich, Michaela C. Steiner, Tomaz Curk, Ina Poser, Kathi 
Zarnack, and Karla M. Neugebauer. 2016. “SR Proteins Are NXF1 Adaptors That 
Link Alternative RNA Processing to MRNA Export.” Genes and Development. 
https://doi.org/10.1101/gad.276477.115. 
Nostrand, Eric L. Van, Gabriel A. Pratt, Alexander A. Shishkin, Chelsea Gelboin-
Burkhart, Mark Y. Fang, Balaji Sundararaman, Steven M. Blue, et al. 2016. “Robust 
Transcriptome-Wide Discovery of RNA-Binding Protein Binding Sites with 




Oslowski, Christine M, and Fumihiko Urano. 2011. Measuring ER Stress and the 
Unfolded Protein Response Using Mammalian Tissue Culture System. Methods in 
Enzymology. 1st ed. Vol. 490. Elsevier Inc. https://doi.org/10.1016/B978-0-12-
385114-7.00004-0. 
Pan, Qun, Ofer Shai, Leo J. Lee, Brendan J. Frey, and Benjamin J. Blencowe. 2008. 
“Deep Surveying of Alternative Splicing Complexity in the Human Transcriptome by 
High-Throughput Sequencing.” Nature Genetics. https://doi.org/10.1038/ng.259. 
Patterson, Ruth E., and Dorothy D. Sears. 2017. “Metabolic Effects of Intermittent 
Fasting.” Annual Review of Nutrition. Annual Reviews Inc. 
https://doi.org/10.1146/annurev-nutr-071816-064634. 
Poisson, Johanne, Sara Lemoinne, Chantal Boulanger, François Durand, Richard 
Moreau, Dominique Valla, and Pierre Emmanuel Rautou. 2017. “Liver Sinusoidal 
Endothelial Cells: Physiology and Role in Liver Diseases.” Journal of Hepatology. 
https://doi.org/10.1016/j.jhep.2016.07.009. 
Postic, Catherine, Masakazu Shiota, Kevin D. Niswender, Thomas L. Jetton, Yeujin 
Chen, J. Michael Moates, Kathy D. Shelton, Jill Lindner, Alan D. Cherrington, and 
Mark A. Magnuson. 1999. “Dual Roles for Glucokinase in Glucose Homeostasis as 
Determined by Liver and Pancreatic β Cell-Specific Gene Knock-Outs Using Cre 




Raabe, Martin, Laura M. Flynn, Constance H. Zlot, Jinny S. Wong, Murielle M. Véniant, 
Robert L. Hamilton, and Stephen G. Young. 1998. “Knockout of the 
Abetalipoproteinemia Gene in Mice: Reduced Lipoprotein Secretion in 
Heterozygotes and Embryonic Lethality in Homozygotes.” Proceedings of the 
National Academy of Sciences of the United States of America 95 (15): 8686–91. 
https://doi.org/10.1073/pnas.95.15.8686. 
Raudvere, Uku, Liis Kolberg, Ivan Kuzmin, Tambet Arak, Priit Adler, Hedi Peterson, and 
Jaak Vilo. 2019. “G:Profiler: A Web Server for Functional Enrichment Analysis and 
Conversions of Gene Lists (2019 Update).” Nucleic Acids Research 47 (W1): 
W191–98. https://doi.org/10.1093/nar/gkz369. 
Riepe, Celeste, Elena Zelin, Stacia Wyman, David Nguyen, Jin Rui Liang, Phillip 
Frankino, Zuriah Meacham, et al. 2018. “Double Stranded DNA Breaks and 
Genome Editing Trigger Ribosome Remodeling and Translational Shutdown.” 
BioRxiv, December, 486704. https://doi.org/10.1101/486704. 
Rock, Kenneth L., and Hajime Kono. 2008. “The Inflammatory Response to Cell Death.” 
Annual Review of Pathology: Mechanisms of Disease 3 (1): 99–126. 
https://doi.org/10.1146/annurev.pathmechdis.3.121806.151456. 
Ruas, Jorge L., James P. White, Rajesh R. Rao, Sandra Kleiner, Kevin T. Brannan, 
Brooke C. Harrison, Nicholas P. Greene, et al. 2012. “A PGC-1α Isoform Induced 




Samali, Afshin, Una Fitzgerald, Shane Deegan, and Sanjeev Gupta. 2010. “Methods for 
Monitoring Endoplasmic Reticulum Stress and the Unfolded Protein Response.” 
International Journal of Cell Biology 2010: 830307. 
https://doi.org/10.1155/2010/830307. 
Sanchez, R. I., and F. C. Kauffman. 2010. “Regulation of Xenobiotic Metabolism in the 
Liver.” In Comprehensive Toxicology, Second Edition, 9:109–28. Elsevier Inc. 
https://doi.org/10.1016/B978-0-08-046884-6.01005-8. 
Sanford, Jeremy R., Nicola K. Gray, Karsten Beckmann, and Javier F. Cáceres. 2004. 
“A Novel Role for Shuttling SR Proteins in MRNA Translation.” Genes and 
Development 18 (7): 755–68. https://doi.org/10.1101/gad.286404. 
Santos-Pereira, José M., and Andrés Aguilera. 2015. “R Loops: New Modulators of 
Genome Dynamics and Function.” Nature Reviews Genetics. Nature Publishing 
Group. https://doi.org/10.1038/nrg3961. 
Seimetz, Joseph, Waqar Arif, Sushant Bangru, Mikel Hernaez, and Auinash Kalsotra. 
2019. “Cell-Type Specific Polysome Profiling from Mammalian Tissues.” Methods 
155 (February): 131–39. https://doi.org/10.1016/J.YMETH.2018.11.015. 
Sekine, Shigeki, Reiko Ogawa, Rie Ito, Nobuyoshi Hiraoka, Michael T. McManus, Yae 
Kanai, and Matthias Hebrok. 2009. “Disruption of Dicer1 Induces Dysregulated 
Fetal Gene Expression and Promotes Hepatocarcinogenesis.” Gastroenterology 
136 (7): 2304-2315.e4. https://doi.org/10.1053/j.gastro.2009.02.067. 
Sen, Supriya, Hassan Jumaa, and Nicholas J G Webster. 2013. “Splicing Factor SRSF3 
172 
 
Is Crucial for Hepatocyte Differentiation and Metabolic Function.” Nature 
Communications 4 (May 2012): 1336. https://doi.org/10.1038/ncomms2342. 
Shen, Shihao, Juw Won Park, Zhi Xiang Lu, Lan Lin, Michael D. Henry, Ying Nian Wu, 
Qing Zhou, and Yi Xing. 2014. “RMATS: Robust and Flexible Detection of 
Differential Alternative Splicing from Replicate RNA-Seq Data.” Proceedings of the 
National Academy of Sciences of the United States of America 111 (51): E5593–
5601. https://doi.org/10.1073/pnas.1419161111. 
Si-Tayeb, Karim, Frédéric P Lemaigre, and Stephen a Duncan. 2010. “Organogenesis 
and Development of the Liver.” Developmental Cell. 
https://doi.org/10.1016/j.devcel.2010.01.011. 
Sollier, Julie, and Karlene A. Cimprich. 2015. “Breaking Bad: R-Loops and Genome 
Integrity.” Trends in Cell Biology. Elsevier Ltd. 
https://doi.org/10.1016/j.tcb.2015.05.003. 
Soneson, Charlotte, Michael I. Love, and Mark D. Robinson. 2015. “Differential 
Analyses for RNA-Seq: Transcript-Level Estimates Improve Gene-Level 
Inferences.” F1000Research 4 (December): 1521. 
https://doi.org/10.12688/f1000research.7563.1. 
Sundararaman, Balaji, Lijun Zhan, Steven M. Blue, Rebecca Stanton, Keri Elkins, Sara 
Olson, Xintao Wei, et al. 2016. “Resources for the Comprehensive Discovery of 




Tous, Cristina, and Andrés Aguilera. 2007. “Impairment of Transcription Elongation by 
R-Loops in Vitro.” Biochemical and Biophysical Research Communications 360 (2): 
428–32. https://doi.org/10.1016/j.bbrc.2007.06.098. 
Vernon, G, a Baranova, and Z M Younossi. 2011. “Systematic Review: The 
Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-
Alcoholic Steatohepatitis in Adults.” Alimentary Pharmacology & Therapeutics 34 
(3): 274–85. https://doi.org/10.1111/j.1365-2036.2011.04724.x. 
Walsh, Callee M., Amanda L. Suchanek, Travis J. Cyphert, Alison B. Kohan, Wioletta 
Szeszel-Fedorowicz, and Lisa M. Salati. 2013. “Serine Arginine Splicing Factor 3 Is 
Involved in Enhanced Splicing of Glucose-6-Phosphate Dehydrogenase RNA in 
Response to Nutrients and Hormones in Liver.” Journal of Biological Chemistry 288 
(4): 2816–28. https://doi.org/10.1074/jbc.M112.410803. 
Weisend, Carla M, Jean A Kundert, Elena S Suvorova, Justin R Prigge, and Edward E 
Schmidt. 2009. “Cre Activity in Fetal AlbCre Mouse Hepatocytes: Utility for 
Developmental Studies.” Genesis 47 (12): 789–92. 
https://doi.org/10.1002/dvg.20568. 
Wiśniewski, Jacek R, Alexandre Zougman, Nagarjuna Nagaraj, and Matthias Mann. 
2009. “Universal Sample Preparation Method for Proteome Analysis.” Nature 
Methods 6 (5): 359–62. https://doi.org/10.1038/nmeth.1322. 
Xu, Xiangdong, Dongmei Yang, Jian-Hua Ding, Wang Wang, Pao-Hsien Chu, Nancy D 
Dalton, Huan-You Wang, et al. 2005. “ASF/SF2-Regulated CaMKIIdelta Alternative 
174 
 
Splicing Temporally Reprograms Excitation-Contraction Coupling in Cardiac 
Muscle.” Cell 120 (1): 59–72. https://doi.org/10.1016/j.cell.2004.11.036. 
Yu, Chi Yi, Elizabeth Theusch, Kathleen Lo, Lara M. Mangravite, Devesh Naidoo, 
Mariya Kutilova, and Marisa W. Medina. 2014. “HNRNPA1 Regulates HMGCR 
Alternative Splicing and Modulates Cellular Cholesterol Metabolism.” Human 
Molecular Genetics. https://doi.org/10.1093/hmg/ddt422. 
Zahler, a M, W S Lane, J a Stolk, and M B Roth. 1992. “SR Proteins: A Conserved 
Family of Pre-MRNA Splicing Factors.” Genes & Development 6 (5): 837–47. 
https://doi.org/10.1101/gad.6.5.837. 
Zhou, Lingyan, Congcong Li, Ling Gao, and Aihong Wang. 2015. “High-Density 
Lipoprotein Synthesis and Metabolism (Review).” Molecular Medicine Reports. 
Spandidos Publications. https://doi.org/10.3892/mmr.2015.3930. 
 
